Surfing the MASH Tsunami
By SurfingNASH.com
Listen to a podcast, please open Podcast Republic app. Available on Google Play Store and Apple App Store.
Image by SurfingNASH.com
Category: Medicine
Open in Apple Podcasts
Open RSS feed
Open Website
Rate for this podcast
Subscribers: 2
Reviews: 0
Episodes: 1073
Description
Driving the Discussion in Fatty Liver Disease. Join hepatology researcher and Key Opinion Leader Jörn Schattenberg, Liver Wellness Advocate Louise Campbell, and Forecasting and Pricing Guru Roger Green and a global group of Key Opinion Leaders and patient advocates as they discuss key issues in Fatty Liver disease, including epidemiology, drug development, clinical pathways, non-invasive testing, health economics and regulatory issues, from their own unique perspectives on the Surfing the MASH Tsunami podcast. #MASH #MAFLD #FattyLiver #livertwitter #AASLD #GlobalLiver #NoNASH #EASL
| Episode | Date |
|---|---|
|
S6.14.3 - Louise and Roger React to Empowered SLD Patient Advocates
|
Oct 07, 2025 |
|
S6.14.2 - Goals of the Stephen A. Harrison Patient Advocacy Fellowship Program
|
Oct 07, 2025 |
|
S6.14.1 - How the Harrison Patient Advocacy Fellowship Came To Be
|
Oct 07, 2025 |
|
S6.14 - Introducing the Dr. Stephen A. Harrison Patient Advocacy Fellowship Program
|
Oct 03, 2025 |
|
S6.13.3 - Major Issues in MASH-ville: US Government Chaos and Scanning Market Dynamism
|
Sep 11, 2025 |
|
S6.13.2 - Newsmakers: Updating Our Approach to Screening for Advanced Liver Disease
|
Sep 09, 2025 |
|
S6.13.1 - Major Issues in MASH-ville: Developing a More Integrated Approach to MASH Patient Management
|
Sep 09, 2025 |
|
S6.13 - Locating MASH patients, Population Screening for Advanced Disease, Impact of Washington on Americans' Health
|
Sep 05, 2025 |
|
S6.12.3 - After the Semaglutide Approval: What Next For MASH Therapy?
|
Sep 02, 2025 |
|
S6.12.2 - After the Semaglutide Approval: Expanding MASH Awareness Will Change Medical Practices
|
Aug 31, 2025 |
|
S6.12.1 - After the Semaglutide Approval: Impact on Patients and Pharmacotherapy
|
Aug 31, 2025 |
|
6.12 - A Second US Drug Approval! What Semaglutide's Success Portends For MASLD Care in the US
|
Aug 29, 2025 |
|
6.11.3 - Expert: Emily Andaya Asks Why There Is No "L" In the (Multi-Meatbolic) CKM Initiative
|
Aug 17, 2025 |
|
6.11.2 - Multi-Metabolic Week Part II: Benefits of the Multi-Metabolic Approach
|
Aug 17, 2025 |
|
6.11.1 - Multi-Metabolic Week Part I: Role of MASLD In Multi-Metabolic Clinics
|
Aug 16, 2025 |
|
6.11 - Multi-Metabolic Practices Integrate MASLD with Other Non-Communicable Diseases
|
Aug 15, 2025 |
|
6.10.3 - Expert: Tim Jobson on Using Basic Data and Analytics to Identify At-Risk Patients
|
Aug 10, 2025 |
|
6.10.2 - Newsmakers: LiverRight Launches America's First Virtual Hepatology Clinic
|
Aug 09, 2025 |
|
6.10.1 - FIrst Six Months, Part I: The Promise of Proteomics For Developing Individualized Treatment Plans
|
Aug 09, 2025 |
|
6.10 - New Approaches to Patient Care: NIT-driven drug choices, Virtual Clinics, Large-Scale Screening
|
Aug 08, 2025 |
|
6.9.3 - Expert: Naim Alkhouri Discusses His Long Friendship with Stephen Harrison and His New Role at Summit Clinical Research
|
Aug 06, 2025 |
|
6.9.2 - Newsmaker: Fatty Liver Alliance President Mike Betel Discusses His 3rd Annual 30-Day Glucose Challenge
|
Aug 05, 2025 |
|
6.9.1 - #SLDThinkTank2025, Part III: Unique Challenge of Nutrition Management and Role Politicians Can Play
|
Aug 05, 2025 |
|
6.9 - Complexities of Behavior Change, Devices That Can Help, Future of Clinical Trials and MedEd
|
Aug 01, 2025 |
|
6.8.3 - Deep Dive into Drug Development IV: Other Modes Of Action; Metabolic vs. Pleiotropic Effects
|
Jul 29, 2025 |
|
6.8.2 - Newsmaker: GLI President and CEO Larry Holden discusses Changes in Washington and How We Can Proceed
|
Jul 28, 2025 |
|
6.8.1 - #SLDThinkTank2025 Part II: Complexities and Challenges of Behavior Change
|
Jul 28, 2025 |
|
6.8 - Hybrid Interventions; Washington Challenges; Two-Target Treatment
|
Jul 26, 2025 |
|
S6 - E7.3 - Deep Dive into Drug Development, Part III: NITs in Drug Development
|
Jul 25, 2025 |
|
S6 - E7.2 - Patient Advocate Jose Willemse on Patient-Centered Care
|
Jul 22, 2025 |
|
S6 - E7.1 - #SLDThinkTank2025 Part I: Hybrid Interventions Integrate AI and Human Care
|
Jul 22, 2025 |
|
S6 - E7 - Barcelona SLD Conference Highlight; NITs in Drug Development
|
Jul 17, 2025 |
|
S6 - E6 - Remembering Stephen Harrison and His Many Contributions to MASH
|
Apr 26, 2025 |
|
S6 - E5.2 - Newsmaker: Naga Chalasani on Real-World Experience Prescribing Resmetirom
|
Apr 24, 2025 |
|
S6 - E5.3 - Expert: Scott Friedman on Gene Therapy and Advances in Liver Science
|
Apr 24, 2025 |
|
S6 - E5.1 - FGF-21s and A Promising Future on Cirrhosis
|
Apr 22, 2025 |
|
S6 - E5 - Drug Development Week: FGF-21s, Cirrhosis, Resmiterom, Gene Therapies
|
Apr 18, 2025 |
|
S6 - E4.3 - Expert: Mazen Noureddin Reviews the Exciting MASLD Drug Development Environment
|
Apr 13, 2025 |
|
S6 - E4.2 - Newsmaker: Fatty Liver Alliance Founder Mike Betel Discusses the Increased Visibility of Patient Advocates
|
Apr 12, 2025 |
|
S6 - E4.1 - MASLD Drugs, SLD Spectrum Insights Suggest Bright Future
|
Apr 12, 2025 |
|
S6 - E4 - Reasons for optimism in MASLD drug development and patient advocacy
|
Apr 11, 2025 |
|
S6 - E3.3 - Expert: GLI's Jeff McIntyre discusses implications of FDA job cuts on MASH drugs
|
Apr 06, 2025 |
|
S6 E3.2 - Newsmakers: FibroSIGHT™ Brings Clinical Trial Analytics to the Clinic
|
Apr 05, 2025 |
|
S6- E3.1 - Roundtable: Spotting Tomorrow’s Trends in Today's MASLD Studies
|
Apr 05, 2025 |
|
S6 - E3 - Drugs and Diagnostics Evolve as the FDA Devolves
|
Apr 04, 2025 |
|
S6 - E2 - MetALD Epidemiology, MASLD Mortality and a PCP "Unicorn"
|
Mar 28, 2025 |
|
S6 - E1: Two Multispecialty February Conferences and Europe Prepares for Resmetirom
|
Mar 21, 2025 |
|
S5 - E26.5 - Looking Back at #TLM2024 - Promoting Healthy Livers and Looking Ahead to 2025
|
Jan 03, 2025 |
|
S5 - E26.4 - Looking Back at #TLM2024 - Patient Advocacy and Patient-Centric Trials
|
Jan 03, 2025 |
|
S5 - E26.2 - Looking Back at #TLM2024 - Patient Genotyping and MASH Clusters
|
Jan 02, 2025 |
|
S5 - E26.3 - Looking Back at #TLM2024 - FGF-21 Agents and the FDA Corner
|
Jan 02, 2025 |
|
S5 - E26.1 - Looking Back at #TLM2024 - Semaglutide Passes the ESSENCE Test
|
Jan 02, 2025 |
|
S5-26 - One Month Later: Looking Back at MASLD/MASH Coverage From The Liver Meeting 2024
|
Dec 20, 2024 |
|
S5 - E25 - Reviewing Expert Recommendations on the Use of Resmetirom
|
Aug 09, 2024 |
|
S4 - E24.5 - SurfingMASH Question of The Week: Keys to Improving Provider-Patient Communication
|
Aug 08, 2024 |
|
S5 - E24.4 - EASL Congress Six Weeks Later: Jeff McIntyre's Key Implications for GLI
|
Aug 08, 2024 |
|
S5 - E24.3 - EASL Congress Six Weeks Later: Jeff McIntyre's Key Takeaways
|
Aug 07, 2024 |
|
S5 - E24.2 - EASL Congress Six Weeks Later: Mathieu Petitjean's Key Implications
|
Aug 07, 2024 |
|
S5 - E24.1 - EASL Congress Six Weeks Later: Mathieu Petitjean's Key Takeaways
|
Aug 07, 2024 |
|
S5 - E24 - A view of MASLD: Looking back at EASL Congress from six weeks later
|
Aug 03, 2024 |
|
S5 SPECIAL 5 - Reviewing EASL Congress: Louise Campbell 3 (first-time material)
|
Jul 21, 2024 |
|
S5 SPECIAL 4 - Reviewing EASL Congress: Sven Francque
|
Jul 20, 2024 |
|
S5 SPECIAL 3 - Reviewing EASL Congress: Louise Campbell 2
|
Jul 20, 2024 |
|
S5 SPECIAL 2 - Reviewing EASL Congress: Louise Campbell I
|
Jul 19, 2024 |
|
S5 SPECIAL 1 - Reviewing EASL Congress: Mike Betel
|
Jul 19, 2024 |
|
S5 - E23.6 - From The Vault: Improving Patient Self-Management And Key Takeaways On Nutrition For MASH Resolution
|
Jul 16, 2024 |
|
S5 - E23.5 - From the EASL Congress: The Need for Shared Experience MASLD Support Groups and Programs
|
Jul 16, 2024 |
|
S5 - E23.4 - From the EASL Congress: Socioeconomic And Psychological Issues In The Physician-Patient Dialogue
|
Jul 16, 2024 |
|
S5 - E23.3 - From The EASL Congress: Improving The Physician-Patient Dialogue
|
Jul 15, 2024 |
|
S5 - E23.2 - From The EASL Congress: Dynamics Of The Physician-Patient Dialogue
|
Jul 15, 2024 |
|
S5 - E23.1 - From The EASL Congress: Overview Of Challenges In Physician-Patient Communication
|
Jul 15, 2024 |
|
S5 - E23 - Lessons from EASL Congress: Challenges in Provider-Patient Communication
|
Jul 12, 2024 |
|
S5 - E22.6 - FROM THE VAULT: Patient Advocates Reflect On How The "System" Views MASH
|
Jul 08, 2024 |
|
S5 - E22.5 - Healthy Livers, Healthy Lives: Watershed Moments To Come In MASLD Publlc Policy
|
Jul 08, 2024 |
|
S5 - E22.4 - Healthy Livers, Healthy Lives: The Role Of The Updated EASL MASLD Guidelines And Big Data
|
Jul 07, 2024 |
|
S5 - E22.3 - Healthy Livers, Healthy Lives: Challenges and Promise in Building a Global MASLD Health Policy
|
Jul 07, 2024 |
|
S5 - E22.2 - Healthy Livers, Healthy Lives: "Political Will" In MASLD Public Policy
|
Jul 07, 2024 |
|
S5 - E22.1 - Healthy Livers, Healthy Lives: Why MASHville Needs This Coalition
|
Jul 07, 2024 |
|
S5 - E22 - Healthy Livers, Healthy Lives: A Global SLD Public Health Coalition
|
Jul 04, 2024 |
|
S5 - E21.6 - From The Vault: Comments On The 2023 AASLD Revised Practice Guidance
|
Jun 30, 2024 |
|
S5 - E21.5 - The Updated MASLD CPG: Implications For Healthcare Systems
|
Jun 30, 2024 |
|
S5 - E21.4 - The Updated MASLD CPG: Pharmacology And New Educational Needs
|
Jun 30, 2024 |
|
S5 - E21.3 - The Updated MASLD CPG: Screening, Diagnosing And Managing Patients
|
Jun 29, 2024 |
|
S5 - E21.2 - The Updated MASLD CPG: Benefits Of The Collaboration
|
Jun 29, 2024 |
|
S5 - E21.1 - The Updated MASLD CPG: Introductions
|
Jun 29, 2024 |
|
S5 - E21 - Reviewing The Updated ESL-EASD-EASO MASLD Clinical Practice Guidelines
|
Jun 27, 2024 |
|
S5 - E20.6 - From the Vault: FGF-21s and "Twin-cretins" At EASL Congress 2023
|
Jun 23, 2024 |
|
S5 - E20.5 - Drug Development Highlights From EASL Congress 2024: Denifenstat, SPECIAL and Other Stories
|
Jun 23, 2024 |
|
S5 - E20.4 - Drug Development Highlights From EASL Congress 2024: Are FGF-21s Induction Therapy or a "MASH Cure"?
|
Jun 23, 2024 |
|
S5 - E20.3 - Drug Development Highlights From EASL Congress 2024: "Twin-cretins" and efruxifermin
|
Jun 22, 2024 |
|
S5 - E20.2 - Drug Development Highlights From EASL Congress 2024: Tirzepatidate and other "Twin-cretins"
|
Jun 22, 2024 |
|
S5 - E20.1 - Drug Development Highlights From EASL Congress 2024: Resmetirom
|
Jun 22, 2024 |
|
S5 - E20 - Lessons From EASL Congress 2024: Exciting Advances in Drug Development
|
Jun 20, 2024 |
|
EASL Congress 2024: Interviews From A Seminal Meeting For MASLD & MASH
|
Jun 13, 2024 |
|
S5 - E18.5 - How Listeners Can Support HOPE, A Unique Support Community For People Who Have Harmed Their Bodies Through Alcohol Use Disorder
|
Jun 11, 2024 |
|
S5 - E18.4 - The Future Of HOPE: Expanding the Support Community for Patients Who Have Harmed Their Bodies Through Alcohol Use Disorder
|
Jun 11, 2024 |
|
S5 - E18.3 - Specific Support Elements HOPE Provides For People Who Have Harmed Themselves Due To Alcohol Use Disorder
|
Jun 11, 2024 |
|
S5 - E18.2 - Why People Who Have Harmed Themselves Through Alcohol Use Disorder Need HOPE
|
Jun 11, 2024 |
|
S5 - E18.1 - Introducing HOPE, A Project For People Who Have Harmed Their Bodies Through Alcohol Use DIsorder
|
Jun 11, 2024 |
|
S5 - E18 - Introducing HOPE, a support program for patients living with the effects of ALD and cirrhosis
|
Jun 06, 2024 |
|
S5 - E17.6 - From The Vault: Looking Back At The EASL Congress 2023 Preview & Program Design
|
Jun 02, 2024 |
|
S5 - E17.5 - Previewing EASL Congress 2024: Focusing On MASLD Drug Development
|
Jun 02, 2024 |
|
S5 - E17.4 - Previewing EASL Congress 2024: Is Big Data The Future Of MASLD?
|
Jun 02, 2024 |
|
S5 - E17.3 - Previewing EASL Congress 2024: Jörn Schattenberg Joins The MASLD Conversation
|
Jun 01, 2024 |
|
S5 - E17.2 - Previewing EASL Congress 2024: Collegiality, Consortia & High-Quality MASLD Abstracts
|
Jun 01, 2024 |
|
S5 - E17.1 - Previewing EASL Congress 2024: Secretary General Aleksander Krag Shares His Vision For The Congress
|
Jun 01, 2024 |
|
S5 - E17 - Previewing EASL Congress 2024 and its Major MASLD Moments
|
May 30, 2024 |
|
S5 - E16.5 - From The Vault: Stephen Harrison Discusses FASCINATE-2 Results For Denifenstat
|
May 26, 2024 |
|
S5 - E16.4 - Remembering MASLD Master Stephen Harrison: Stephen As Role Model
|
May 26, 2024 |
|
S5 - E16.3 - Remembering MASLD Master Stephen Harrison: Stephen As Innovator
|
May 25, 2024 |
|
S5 - E16.2 - Remembering MASLD Master Stephen Harrison: Stephen As Patient Advocate
|
May 25, 2024 |
|
S5 - E16.1 - Remembering MASLD Master Stephen Harrison: Stephen As Integrator
|
May 25, 2024 |
|
S5 - E16 - Remembering Stephen Harrison 2: More Memories of a MASLD Master
|
May 23, 2024 |
|
S5-15.6 - From the Vault: Discussing NAIL-NIT Findings at INCBCN 2023
|
May 19, 2024 |
|
S5 - E15.5 - From SLD Think-Tank 2024 Wrap-Pp: Shall We Focus More on Preventive Hepatology?
|
May 19, 2024 |
|
S5 - E15.4 - From SLD Think-Tank 2024: Improving Preparedness And The Value of Having Rezdiffra
|
May 19, 2024 |
|
S5 - E15.3 - From SLD Think-Tank 2024: Meeting Agenda And The "Magic Wand"
|
May 18, 2024 |
|
S5 - E15.2 - From SLD Think-Tank 2024: An Innovative Stimulating Meeting Design
|
May 18, 2024 |
|
S5 - E15.1 - From SLD Think-Tank 2024: Meet Maja Thiele And Learn About LiverAIM
|
May 18, 2024 |
|
S5 - E15 - Highlights from SLD Think-Tank 2024, a Public Health Approach to MASH
|
May 16, 2024 |
|
S5 - E14.4 - From the Vault: Our Last Year-End Interview With MASH Master Stephen Harrison
|
May 12, 2024 |
|
S5 E14.2 - Remembering Stephen Harrison: Professional Accomplishments
|
May 12, 2024 |
|
S5 E14.1 - Remembering Stephen Harrison: Personal Memories
|
May 12, 2024 |
|
S5 - E14.3 - Remembering Stephen Harrison: "Harrisonisms"
|
May 11, 2024 |
|
S5 - E14 - Remembering Stephen Harrison - colleagues share memories and impressions of an SLD master
|
May 08, 2024 |
|
S5 - E13.6 - One Year Ago: When Global Fatty Liver Day Was #NASHDay 2023
|
May 06, 2024 |
|
S5 - E13.5 - MASH And The Elephant Metaphor: Attacking A Multi-Faceted, Complex Disease
|
May 05, 2024 |
|
S5 - E13.4 - A Deeper Dive into Care Challenges and Barriers Affecting MASH Patient Care
|
May 05, 2024 |
|
S5 - E13.3 - Practical Challenges In Patient Care: Role Of GLP-1s And Scanning
|
May 04, 2024 |
|
S5 - E13.2 - Global Fatty Liver Day 2024 And The Rationale Behind "Act Now. Get Screened."
|
May 04, 2024 |
|
S5 - E13.1 - Remembering SurfingMASH Co-Founder Stephen Harrison
|
May 04, 2024 |
|
S5 - E13 - Previewing Global Fatty Liver Day 2024
|
May 02, 2024 |
|
S5 - E12.6 - From The Vault: More Different Roles For NITs In MASH
|
Apr 28, 2024 |
|
S5 - E12.5 - MASH Drug Development: Combining With Old Drugs And Shortening Time To Approval
|
Apr 28, 2024 |
|
S5 - E12.4 - MASH Drug Development: Implications Of Concomitant Metabolic Therapy Use
|
Apr 28, 2024 |
|
S5 - E15.3 - MASH Drug Development: Improvement Since 2020 And Issues That Remain
|
Apr 27, 2024 |
|
S5 - E12.2 - MASH Drug Development: Improving Efficacy Endpoints
|
Apr 27, 2024 |
|
S5 - E12.1 - MASH Drug Development: The State Of The Graveyard 2023
|
Apr 27, 2024 |
|
S5 - E12 - MASH Drug Development: What Failures Taught Us About Success
|
Apr 25, 2024 |
|
S5 - E11.6 - From The Vault: Another Strategic Role For Prescribing MASH Drugs
|
Apr 21, 2024 |
|
S5 - E11.5 - MASH Prescribing Models & The Increasing Challenge Of Keeping Patients In Long-Term Clinical Trials
|
Apr 21, 2024 |
|
S5 - E11.4 - More Hot MASLD Topics: Inflammation, MD columnists' Advice, FGF-21s
|
Apr 21, 2024 |
|
S5 - E11.3 - Panelists' Hot Topics: Low-Dose Aspirin, SLD Think Tank, Dietary Inflammation Index
|
Apr 20, 2024 |
|
S5 - E11.2 - Defining Therapeutic Futility For Rezdiffra And Discussing Advances In MASLD Translational Medicine
|
Apr 20, 2024 |
|
S5 - E11.1 - How The Rezdiffra Approval Has Affected How One Clinic Manages MASH Patients
|
Apr 20, 2024 |
|
S5 - E11 - Life With Rezdiffra: Early Impact On MASH Patient Treatment and MASLD Clinical Trials
|
Apr 18, 2024 |
|
S5 - E10 - Lessons And Insights On Using Basic EHR Data To Screen For Target MASLD Patients
|
Apr 15, 2024 |
|
S5 - E9.6 - From The Vault: An Earlier Look At Screening In The Clinical Care Pathway
|
Apr 07, 2024 |
|
S5 - E9.5 - In-Office Screening Post-Rezdiffra: The Importance Of Predictive Biomarkers
|
Apr 07, 2024 |
|
S5 - E9.4 - In-office MASLD Screening and the Clinical Care Pathway
|
Apr 07, 2024 |
|
S5 - E9.3 - How Will Increased Access To In-Office Scanning Improve MASLD Therapy:
|
Apr 06, 2024 |
|
S5 - E9.2 - VCTE Studies Demonstrate That Multiple Nutrition Interventions Can Support MASLD Patients
|
Apr 06, 2024 |
|
S5 - E9.1 - VCTE As A Prognostic And Therapeutic Tool For MASLD
|
Apr 06, 2024 |
|
S5 - E9 - Value of VCTE Or Other In-Office MASLD Monitoring
|
Apr 04, 2024 |
|
S5 - E8 - Changing Patient Incentives For Participating In MASH Clinical Trials
|
Apr 01, 2024 |
|
S5 - E7.6 - MASLD Patient Advocates' Recommendations for Others after Rezdiffra Approval
|
Mar 24, 2024 |
|
S5 - E7.5 - Will Increasing the Focus on MASH via Rezdiffra Overwhelm the Healthcare System?
|
Mar 24, 2024 |
|
S5 - E7.4 - How MASH patient advocates plan to support Rezdiffra
|
Mar 24, 2024 |
|
S5 - E7.3 - Patient advocacy and the Rezdiffra label
|
Mar 23, 2024 |
|
S5 - E7.1 - Rezdiffra is approved! How patient and their advocates processed the news about the first MASH drug
|
Mar 23, 2024 |
|
S5 - E7.2 - Identifying the target MASH patients for Rezdiffra
|
Mar 23, 2024 |
|
S5 - E7 - MASLD Patient Advocates Celebrate Rezdiffra and Discuss the Future
|
Mar 21, 2024 |
|
S5 - E6.6 - Closing Question From The Episode On Rezdiffra, The First MASH Drug
|
Mar 19, 2024 |
|
S5 - E6.5 - BioPharma Industry Takeaways ForBioPharma Industry Takeaways From The Rezdiffra Launch The Rezdiffra Launch
|
Mar 19, 2024 |
|
S5 - E6.4 - Finding The MASH Patients That Are The Initial Rezdiffra Targets
|
Mar 19, 2024 |
|
S5 - E6.3 - Staging and screening patients for Rezdiffra using NITs
|
Mar 18, 2024 |
|
S5 - E6.2 - How Approval Of Rezdiffra,The First MASH Drug, Might Improve Patient Adherence To Lifestyle Recommendations
|
Mar 18, 2024 |
|
S5 - E6.1 - Rezdiffra Is Approved! How Key Opinion Leaders Processed The News About The First MASH Drug
|
Mar 18, 2024 |
|
S5 - E6 - Rezdiffra Is Here! Key Opinion Leaders React To The First MASH Drug Approval
|
Mar 16, 2024 |
|
S5 - E5.6 - From The Vault: Tsunami's First Look At MASEF, A Major New NIT
|
Mar 10, 2024 |
|
S5 - E5.5 - More on GLP-1s and a Broader MASH Wrap-up
|
Mar 10, 2024 |
|
S5 - E5.4 - The dance of drug pricing and patient targets in MASH, PLUS: the role of GLP-1s
|
Mar 10, 2024 |
|
S5 - E5.3 - Strategies to Improve NIT reliability in Diagnosing and Staging MASH Fibrosis
|
Mar 10, 2024 |
|
S5 - E5.2 - NITs In The Diagnosis and Treatment Of Advanced MASH Fibrosis Patients
|
Mar 10, 2024 |
|
S5 - E5.1 - Why We Are Focusing On NITs For MASH Diagnosis And Screening
|
Mar 10, 2024 |
|
S5 - E5 - How Non-Invasive Tests (NITs) For MASLD And MASH Might Evolve In 2024
|
Mar 07, 2024 |
|
S5 - E4.6 - From The Vault: What a NASH Disease Model Reveals About Treating Advanced Fibrosis
|
Mar 03, 2024 |
|
S5 - E4.5 - MASH Education As A Tool To Stem The MASLD Pandemic
|
Mar 03, 2024 |
|
S5 - E 4.4 - Learning about the Global NASH Council's work in MASLD
|
Mar 03, 2024 |
|
S5 - E4.1 - Appreciating The Disease Burden Of MASLD
|
Mar 03, 2024 |
|
S5 - E4.2 - The Breadth Of MASLD Disease Burden And Cost Effectiveness Of Therapies
|
Mar 03, 2024 |
|
S5 - E4.3 - Slowing The Growth Of The MASLD Pandemic
|
Mar 03, 2024 |
|
S5 - E4 - MASLD Epidemiology Takes: Rapidly Proliferating Prevalence; Many Public Health Needs
|
Feb 29, 2024 |
|
S5 - E3.6 - From the Vault: EASL Congress 2023: Focus On The New MASLD Nomenclature
|
Feb 27, 2024 |
|
S5 - E3.5 - The New MASLD Nomenclature: What Lies Ahead For MASH Patients And Providers?
|
Feb 27, 2024 |
|
S5 - E3.4 - Discussing MASLD With Patients: MASH Is Not "Just A Little Fat" Any More
|
Feb 27, 2024 |
|
S5 - E3.3 - The New MASLD Nomenclature -- MASLD Rollout And Stakeholder Roles
|
Feb 27, 2024 |
|
S5 - E3.2 - How Did The Delphi Process Work For The New MASLD Nomenclature?
|
Feb 27, 2024 |
|
S5 - E3.1 - Why create a new MASLD nomenclature?
|
Feb 26, 2024 |
|
S5 - E3 - The New MASLD Nomenclature And How We Got Here
|
Feb 24, 2024 |
|
S5 - E2.5 - Conversations From The Vault: Jeff McIntyre On ICER Reviews And NITs
|
Feb 19, 2024 |
|
S5 - E2.4 - MASLD Patient Advocates' Priority 2024 MASH Programs
|
Feb 18, 2024 |
|
S5 - E2.3 - Where Do MASLD Patients And Advocates Fit In MASH Drug Access Decisions?
|
Feb 17, 2024 |
|
S5 - E2.2 - After The First MASH Drug Approval, Focus Shifts To Patient Access
|
Feb 17, 2024 |
|
S5 - E2.1 - Expectations For The Resmetirom PDUFA Date - The First MASH Drug Approval?
|
Feb 17, 2024 |
|
S5 - E02 - MASLD Patient Advocates Plan MASH Activities For 2024
|
Feb 15, 2024 |
|
S5 - E1.6 - SurfingMASH Is Back! How Can Consumer Behavior Confound MASH Care?
|
Feb 11, 2024 |
|
S5 -E1.5 - SurfingMASH Is Back! How Will GLP-1 Ads From Telemedicine Affect MASH?
|
Feb 11, 2024 |
|
S5 - E1.4 - SurfingMASH Is Back! Reframing "Liver Awareness" In The Context Of US DTC Advertising
|
Feb 11, 2024 |
|
S5 - E1.3 - SurfingMASH Is Back! 2024 Podcast Updates And The Increasing Need For "Liver Awareness"
|
Feb 10, 2024 |
|
S5 - E1.2 - SurfingMASH Is Back! Louise Campbell Discusses Building MyLife365.Me And Expanding To New Markets
|
Feb 10, 2024 |
|
S5 - E1.1 - SurfingMASH Is Back! Jörn Schattenberg On Becoming Department Director At Saarlands
|
Feb 10, 2024 |
|
S5 - E1 - How might approval of a MASH drug affect patient treatment?
|
Feb 08, 2024 |
|
S4 E50.11 - Wrapping Up 2023 - An Interview with Global Liver Institute Vice President, Liver Health Programs, Jeff McIntyre
|
Jan 17, 2024 |
|
S4 E50.10 - Wrapping Up 2023 - An Interview with Ukraine Public Health Executive Tetiana Deshko
|
Jan 16, 2024 |
|
S4 E50.9 - Wrapping Up 2023 - An Interview With Novo Nordisk International Medical VP Michelle Long
|
Jan 16, 2024 |
|
S4 E50.8 - Wrapping Up 2023 - An Interview With Biotech Entrepreneur Rachel Zayas
|
Jan 15, 2024 |
|
S4 E50.7 - Wrapping Up 2023 - An Interview with Donna Cryer
|
Dec 28, 2023 |
|
S4 E50.6 - Wrapping Up 2023 - An Interview With Neeraj Mistry And Jenn Leigh Jones
|
Dec 28, 2023 |
|
S4 E50.5 - Wrapping Up 2023 - An Interview with Hannes Hagstrom
|
Dec 27, 2023 |
|
S4 E50.4 - Wrapping Up 2023 - An Interview With Dean Tai
|
Dec 27, 2023 |
|
S4 E50.3 - Wrapping Up 2023 - An Interview With Naim Alkhouri
|
Dec 23, 2023 |
|
S4 E50.2 - Wrapping Up 2023 - An Interview with Mike Betel and Tony Villiotti
|
Dec 22, 2023 |
|
S4 - E50.1 - Wrapping Up 2023 in Steatotic Liver Disease: A Discussion with Jeff Lazarus
|
Dec 20, 2023 |
|
S4-E49.6 - Conversations From The Vault -- NITs At TLM2022
|
Dec 03, 2023 |
|
S4-E49.5 - TLM2023 Wrap-Up - Panel Discusses New Nomenclature, Impact Of Triple Agonists
|
Dec 03, 2023 |
|
S4-E49.4 - TLM2023 Wrap-Up - Panel Discusses Liver Science, Other Issues
|
Dec 03, 2023 |
|
S4-E49.3 - TLM2023 Wrap-Up - Panel Discusses NITs, AI And Bariatric Surgery
|
Dec 03, 2023 |
|
S4-E49.2 - TLM2023 Wrap-Up - Panel Discusses Medicines
|
Dec 03, 2023 |
|
S4-E49.1 - TLM2023 Wrap-Up - Panel Discusses General Impressions
|
Dec 02, 2023 |
|
S4-E49 - Wrapping Up TLM 2023 - A Panel Discussion With Scott Friedman And Laurent Castera
|
Dec 01, 2023 |
|
S4-E48.3 - Reviewing TLM 2023 Part One (cont.) – A Discussion with Michael Betel
|
Nov 29, 2023 |
|
S4-E48.2 - Reviewing TLM 2023 Part One (Cont.) - A Discussion With Tim Jobson
|
Nov 27, 2023 |
|
S4-E48.1 - Reviewing TLM 2023 Part One -- A Discussion With Zobair Younossi
|
Nov 15, 2023 |
|
S4-E47 - Previewing The Liver Meeting 2023: Abstracts of Interest
|
Nov 09, 2023 |
|
S4-E46.3 - The Liver Meeting 2023: Updates with Key Opinion Leader, Naim Alkhouri
|
Nov 05, 2023 |
|
S4-E46.4 - The Liver Meeting 2023: Updates with Key Opinion Leader, Scott Isaacs
|
Nov 05, 2023 |
|
S4-E46.2 - Anticipating TLM 2023 with Michael Betel
|
Oct 31, 2023 |
|
S4-E46.1 - The Liver Meeting 2023: Updates with Key Opinion Leader, Jörn Schattenberg
|
Oct 30, 2023 |
|
S4-E45.3 - The Impact of War on a Leading Clinical Trial Site
|
Oct 26, 2023 |
|
S4-E45.4 - From the Vault: Tetiana Deshko on the public health care in Ukraine during the invasion
|
Oct 26, 2023 |
|
S4-E45.2 - Hepatology Under Air Raids
|
Oct 25, 2023 |
|
S4-E45.1 - Meeting Professor Oren Shibolet
|
Oct 22, 2023 |
|
S4-E45 - Interview with Oren Shibolet, Head of Gastroenterology and Hepatology at the Tel Aviv Medical Center
|
Oct 21, 2023 |
|
S4-E44.5 - From the Vault: Creating An Early Diagnosis NASH Decision Model
|
Oct 15, 2023 |
|
S4-E44.4 - How does MASH and MASLD differ in women compared to men?
|
Oct 15, 2023 |
|
S4-E44.3 - Roberta Forlano on Different Challenges for Different Patient Populations
|
Oct 14, 2023 |
|
S4-E44.2 - Investigating False Negative Screening Rates
|
Oct 14, 2023 |
|
S4-E44.1 - Introducing Roberta Forlano and a Variety of Compelling Research Interests
|
Oct 14, 2023 |
|
S4-E44 - Screening Strategies for Gender-Based SLD Challenges
|
Oct 11, 2023 |
|
S4-E43.6 - Career Advice on Academia vs Corporate Life
|
Oct 08, 2023 |
|
S4-E43.5 - Corporate life vs academia: which is right for who?
|
Oct 08, 2023 |
|
S4-E43.4 - Michelle Long on Academia vs Industry
|
Oct 08, 2023 |
|
S4-E43.3 - Rachel Zayas on the Trajectory of and Intentionality Behind AGED Diagnostics
|
Oct 07, 2023 |
|
S4-E43.2 - CEO Rachel Zayas on Fundraising and Venture Competitions
|
Oct 07, 2023 |
|
S3-E43.1 - Rachel Zayas on the Product Development Process of AGED Diagnostics
|
Oct 07, 2023 |
|
S4-E43 - Focus on Career Stories and Entrepreneurship
|
Oct 06, 2023 |
|
S4-E42.4 - Hannes Hagström on the Broad Aperture of the SLD Summit
|
Oct 06, 2023 |
|
S4-E42.5 - Final Recap of the 2023 SLD Summit: Takeaways and Looking Forward
|
Oct 06, 2023 |
|
S4-E42.6 - From the Vault: NAFLD Summit in Context and Learning from Failed Trials
|
Oct 06, 2023 |
|
S4-E42.3 - Diving into Research from the EASL SLD Summit
|
Sep 30, 2023 |
|
S4-E42.2 - MASH, MetALD and Alcoholic SLD: A Continuum?
|
Sep 30, 2023 |
|
S4-E42.1 - Sven Francque on Organizing the EASL SLD Summit
|
Sep 30, 2023 |
|
S4-E42 - EASL SLD Summit 2023
|
Sep 29, 2023 |
|
S4-E41.6 - From the Vault: Highlights from Paris NASH 2021
|
Sep 24, 2023 |
|
S4-E41.5 - Veronica Miller on “why are we validating a surrogate with a surrogate?”
|
Sep 24, 2023 |
|
S4-E41.4 - NITs to Qualify Patients for Trials vs to Evaluate Efficacy of Drugs
|
Sep 24, 2023 |
|
S4-E41.3 - Laurent Castera on the FDA's NIT Workshop
|
Sep 23, 2023 |
|
S4-E41.2 - Naim Alkhouri on clinical trial populations and the future decisions of FDA
|
Sep 23, 2023 |
|
S4-E41.1 - Naim Alkhouri on an NIT-based alternative path to conditional approval
|
Sep 23, 2023 |
|
S4-E41 - Reviewing the FDA's NIT Workshop
|
Sep 22, 2023 |
|
S4-E40.5 - Paris NASH Review: More Topics and Final Thoughts
|
Sep 17, 2023 |
|
S4-E40.4 - Challenges in Treating and Assessing Adequately
|
Sep 17, 2023 |
|
S4-E40.3 - Which test is best for which patients?
|
Sep 16, 2023 |
|
S4-E40.2 - Deeper Dive into the Landscape of NITs
|
Sep 16, 2023 |
|
S4-E40.1 - Liver as a Regenerative Organ and the Use and Limitations of NITs
|
Sep 16, 2023 |
|
S4-E40 - Review of Paris NASH 2023
|
Sep 14, 2023 |
|
S4-E39.4 - MASEF: Where will we be in 2 years?
|
Sep 03, 2023 |
|
S4-E39.3 - MASEF: Next Steps and New Cohorts
|
Sep 03, 2023 |
|
S4-E39.2 - MASEF: Cost Effectiveness and Application Settings
|
Sep 02, 2023 |
|
S4-E39.1 - MASEF: Study Parameters and Notable Results
|
Sep 02, 2023 |
|
S4-E39 - The Metabolomics-Advanced Steatohepatitis Fibrosis Score (MASEF)
|
Aug 31, 2023 |
|
S4-E38.1 - 3 Important Questions to Consider for Full Patient Support
|
Aug 29, 2023 |
|
S4-E38.2 - On the Importance of Multidisciplinary Teams
|
Aug 29, 2023 |
|
S4-E38.3 - Getting the Right Message to the Right Patient at the Right Time
|
Aug 29, 2023 |
|
S4-E38.4 - On the Capabilities of The Health Care Systems
|
Aug 29, 2023 |
|
S4-E38 - Nurses Helping NASH Patients
|
Aug 24, 2023 |
|
S4-E37.4 - NASH Patient Care: The Value of Patient Education
|
Aug 20, 2023 |
|
S4-E37.3 - NASH Patient Education: Liver Nurses’ Roles
|
Aug 19, 2023 |
|
S4-E37.2 - NASH Patient Support: Liver Nursing Challenges
|
Aug 19, 2023 |
|
S4-E37.1 - NASH Patient Support: Meet Today’s Liver Nurses
|
Aug 19, 2023 |
|
S4-E37 - Focus on the Role of Allied Health and Strengthening NASH Education
|
Aug 17, 2023 |
|
S4-E36.6 - From the Vault: NASH Challenges: Early Diagnosis & NASH Patient Management
|
Aug 13, 2023 |
|
S4-E36.5 - LOCATE-NAFLD: What’s Next and Practical Takeaways
|
Aug 13, 2023 |
|
S4-E36.4 - LOCATE-NAFLD: Funding and Generating Data
|
Aug 13, 2023 |
|
S4-E36.3 - LOCATE-NAFLD: Cost Effectiveness and Implementation in Different Systems
|
Aug 12, 2023 |
|
S4-E36.2 - LOCATE-NAFLD: Study Design and Early Analysis
|
Aug 12, 2023 |
|
S4-E36.1 - Meeting James O’Beirne and Introducing the LOCATE-NAFLD Study
|
Aug 12, 2023 |
|
S4-E36 - LOCATE-NAFLD: Improved Models for Patient Identification and Risk Stratification
|
Aug 10, 2023 |
|
S4-E35.4 - Looking Forward at the SurfingNASH Program
|
Aug 06, 2023 |
|
S4-E35.3 - Strengthening Patient Involvement, NIT Development and Lessons from AI
|
Aug 05, 2023 |
|
S4-E35.2 - Challenges Associated with Communicating New Nomenclature
|
Aug 05, 2023 |
|
S4-E35.1 - High-Level Recap of Two Key Events for 2023 Thus Far
|
Aug 05, 2023 |
|
S4-E35.5 - From the Vault: The Psychology of Decision-Making Around Diet and Professional Support
|
Aug 05, 2023 |
|
S4-E35 - SurfingNASH 2023 Year-to-Date Review and Looking Ahead
|
Aug 03, 2023 |
|
S4-E34.6 - From the Vault: Presentation on Efruxifermin in NASH with Fibrosis
|
Jul 31, 2023 |
|
S4-E34.5 - GLP-1s and Lean Muscle Loss
|
Jul 30, 2023 |
|
S4-E34.4 - Pemvidutide and the Importance of the Actual GLP-1-to-Glucagon Impact Ratio
|
Jul 30, 2023 |
|
S4-E34.3 - The Increasing Importance of Omics
|
Jul 29, 2023 |
|
S4-E34.2 - Practical and Plausible Notes On Injectables Versus Oral Agents
|
Jul 29, 2023 |
|
S4-E34.1 - The Excitement of FASN Inhibitors: Positive 2B Interim Data for Denifanstat
|
Jul 29, 2023 |
|
S4-E34 - Drug Development Stories from EASL and ADA: Part 2
|
Jul 27, 2023 |
|
S4-E33.5 - From the Vault: ILC 2022 Looking Back: NASH Is a Complex Disease
|
Jul 23, 2023 |
|
S4-E33.4 - More Presentation Insights on Frequency of Testing, NITs and Biopsy
|
Jul 23, 2023 |
|
S4-E33.3 - Steatotic Liver Disease, HCC and Mechanisms of Fibrosis Resolution
|
Jul 22, 2023 |
|
S4-E33.2 - Unmet Needs in the Primary Care Setting for Disease Identification
|
Jul 22, 2023 |
|
S4-E33.1 - EASL Congress 2023: Focus on New Nomenclature
|
Jul 22, 2023 |
|
S4-E33 - EASL Congress: Nomenclature and More Compelling Presentations
|
Jul 20, 2023 |
|
S4-E32.5 - From the Vault: ILC 2022 Looking Back: Crystal Balling & The Semaglutide Trial
|
Jul 17, 2023 |
|
S4-E32.4 - The Potential of NASH Drugs as Adjuvant Therapy
|
Jul 16, 2023 |
|
S4-E32.3 - Discussing Other Drugs in the Therapeutic Landscape
|
Jul 15, 2023 |
|
S4-E32.2 - Why We Should Develop Deeper Understanding of Liver Volume
|
Jul 15, 2023 |
|
S4-E32.1 - Lead Principle Investigator Stephen Harrison Recaps the MAESTRO-NASH Program for Resmetirom
|
Jul 15, 2023 |
|
S4-E32 - Drug Development Stories from EASL and ADA: Part 1
|
Jul 13, 2023 |
|
S4-E31.4 - EASL Congress and ADA Scientific Sessions: Reshaping the way we think about Fatty Liver Disease
|
Jul 09, 2023 |
|
S4-E31.3 - Jörn Schattenberg on the Therapeutic Landscape and Fibrosis Resolution
|
Jul 09, 2023 |
|
S4-E31.2 - What do we know about mechanisms of action in NASH drugs and the commercial implications?
|
Jul 09, 2023 |
|
S4-E31.1 - Mazen Noureddin on "NASH Monopoly"
|
Jul 09, 2023 |
|
S4-E31 - Mazen Noureddin and Jörn Schattenberg on the Developing Therapeutic Landscape
|
Jul 07, 2023 |
|
S4-E30.4 - EASL Congress 2023: Final Takeaways
|
Jul 02, 2023 |
|
S4-E30.3 - EASL Congress 2023: More Posters and Presentations
|
Jul 02, 2023 |
|
S4-E30.2 - EASL Congress 2023: Scoring Systems to Evaluate NASH
|
Jul 02, 2023 |
|
S4-E30.1 - EASL Congress 2023: Nomenclature Rollout
|
Jul 02, 2023 |
|
S4-E29.3 - EASL Congress 2023: Final Thoughts on Days 1-3
|
Jul 01, 2023 |
|
S4-E29.2 - EASL Congress 2023: Challenges in Patient Screening and the “2nd Wave” of NASH Therapeutics
|
Jul 01, 2023 |
|
S4-E29.1 - EASL Congress 2023: Presentation on MAESTRO-NASH Phase 3 Results
|
Jul 01, 2023 |
|
S4-E30 - EASL Congress 2023: Real-Time Review Part 2
|
Jun 26, 2023 |
|
S4-E29 - EASL Congress 2023: Real-Time Review Part 1
|
Jun 26, 2023 |
|
S4-E28 - Tetiana Deshko on the public health care in Ukraine during the invasion
|
Jun 22, 2023 |
|
S4-E27.6 - Deep Dive into AI and Pathology with Arun Sanyal and David Kleiner
|
Jun 18, 2023 |
|
S4-E27.5 - EASL Congress 2023: Exploring Technology for Identifying Patients
|
Jun 18, 2023 |
|
S4-E27.4 - Previewing EASL Congress 2023 with Louise Campbell: Frontline Screening
|
Jun 18, 2023 |
|
S4-E27.3 - Abstract session - NAFLD: Clinical Aspects
|
Jun 17, 2023 |
|
S4-E27.2 - Abstract session - NAFLD: Therapy
|
Jun 17, 2023 |
|
S4-E27.1 - Unpacking the Program with Ian Rowe and Jörn Schattenberg
|
Jun 17, 2023 |
|
S4-E27 - EASL Congress 2023 Preview: Great Talks to Anticipate!
|
Jun 15, 2023 |
|
S4-E25.5 - Wrap-Up on NICE Guidance for FibroScan
|
Jun 12, 2023 |
|
S4-E25.4 - NICE Guidance for FibroScan: The Devil is in the Details
|
Jun 12, 2023 |
|
S4-E25.3 - The Future of FibroScan and Optimizing Availability of Quality Scanning
|
Jun 12, 2023 |
|
S4-E25.1 - Meeting Vanessa Hebditch and the Role of the British Liver Trust in Fighting for FibroScan
|
Jun 11, 2023 |
|
S4-E25.2 - NICE Guidance for FibroScan: Collecting Data Well and Wisely
|
Jun 11, 2023 |
|
S4-E26.4 - International #NASHDay 2023 Wrap-Up
|
Jun 11, 2023 |
|
S4-E26.3 - FibroScan and the Impact of Socioeconomic Factors on Liver Health
|
Jun 10, 2023 |
|
S4-E26.2 - Discussing the Rise of NAFLD/NASH in Adolescents
|
Jun 10, 2023 |
|
S4-E26.1 - What Patient Advocate Organizations Are Doing Around the World in Support of #NASHDay 2023
|
Jun 10, 2023 |
|
S4-E26 - Patient Advocate Focus on International #NASHDay 2023
|
Jun 09, 2023 |
|
S4-E25 - Exciting News! NICE Guidance Supports FibroScan Use Outside Secondary and Specialist Care in the UK
|
Jun 08, 2023 |
|
S4-E24.6 - From the Vault: Did the Innovations in NAFLD Care Conference Strengthen the Case for an Integrated NAFLD Care Pathway?
|
Jun 04, 2023 |
|
S4-E24.5 - INCBCN Review: Wrap-Up Comments and Moving Forward
|
Jun 04, 2023 |
|
S4-E24.4 - INCBCN Day 2 Summary
|
Jun 04, 2023 |
|
S3-E24.3 - Focus on Preventative Hepatology
|
Jun 03, 2023 |
|
S4-E24.2 - INCBCN Review: NAFLD and Social Drinking
|
Jun 03, 2023 |
|
S4-E24.1 - INCBCN Review: NASH-NITs Real-World-Evidence Summit
|
Jun 03, 2023 |
|
S4-E24 - Reviewing the 2023 Innovations in NAFLD Care Workshop
|
Jun 01, 2023 |
|
S4-E21.5 - From the Vault: ILC 2022 Looking Back: NASH Is a Complex Disease
|
May 28, 2023 |
|
S4-E21.4 - Virtual EASL Congress 2023 and the Power of Posters
|
May 28, 2023 |
|
S4-E21.3 - Curating the EASL 2023 Program and 3 “Can’t Miss” Features
|
May 28, 2023 |
|
S4-E21.2 - Previewing EASL Congress 2023: Highlighting Exciting Elements
|
May 28, 2023 |
|
S4-E21.1 Meeting Aleksander Krag and Setting the Stage for EASL Congress 2023
|
May 28, 2023 |
|
S4-E23.4 - Deep Dive into Hepatocellular Ballooning and the Power of AI
|
May 27, 2023 |
|
S4-E23.3 - Lowering Screen Fail Rates and Guidelines for the Biopsy Reading Process
|
May 27, 2023 |
|
S4-E23.1 - Obeticholic Acid: Is the Juice Worth the Squeeze?
|
May 27, 2023 |
|
S4-E23.2 - The Future of AI-Assisted Digital Pathology and NITs
|
May 27, 2023 |
|
S4-E23 - Stephen Harrison on Challenges and Opportunities in NASH Drug Development
|
May 25, 2023 |
|
S4-E22 - PART 1: FDA ADCOM Meeting for Obeticholic Acid as a Treatment for Pre-Cirrhotic Fibrosis Due to NASH
|
May 22, 2023 |
|
S4-E21 - Surfing NASH Previews EASL Congress 2023
|
May 18, 2023 |
|
S4-E20.6 - From the Vault: Discussing NITs and Final Thoughts on NAFLD Summit
|
May 14, 2023 |
|
S4-E20.5 - Harnessing the Strengths of the Patient Advocate Community
|
May 14, 2023 |
|
S4-E20.4 - Donna Cryer’s Call to Action for Patient Advocacy in the NASH Community
|
May 14, 2023 |
|
S4-E20.3 - Generating and Promoting the Data to Demonstrate Patient Needs
|
May 13, 2023 |
|
S4-E20.2 - Listening to Both Sides: Allied Health for Patient Empowerment
|
May 13, 2023 |
|
S4-E20.1 - Who is going to be the Larry Kramer of NASH?
|
May 13, 2023 |
|
S4-E20 - Leveraging Patient Voice and Needs in the NASH Community
|
May 11, 2023 |
|
S4-E19.6 - From the Vault: REGENERATE Redux: Clearing The Finish Line?
|
May 07, 2023 |
|
S4-E19.5 - Teasing the Difference Between Patient Advocate Voice and Patient Advocate Vote
|
May 07, 2023 |
|
S4-E19.4 - Patient Advocates Describe the Reasoning Behind Their Testimonies
|
May 07, 2023 |
|
S4-E19.3 - The Role of Biopsy in Prescribing NASH Therapeutics
|
May 06, 2023 |
|
S4-E19.2 - Patient Advocates React to the Word “Empathy”
|
May 06, 2023 |
|
S4-E19.1 - How Did the Patient Advocates Come to Offer Testimonies?
|
May 06, 2023 |
|
S4-E19 - Patient Advocate Panel Responds to ICER Draft Report on Resmetirom and Obeticholic Acid for NASH
|
May 04, 2023 |
|
S4-E18.6 - From the Vault: Clinical Care Pathway: What Can Be Done Today?
|
Apr 30, 2023 |
|
S4-E18.5 - Allied Health Professionals and Patient Identification in Endocrinology Clinics
|
Apr 30, 2023 |
|
S4-E18.4 - Empowering Physicians Through Simple Tools and the Demise of Beethoven
|
Apr 30, 2023 |
|
S4-E18.3 - Positive Patient Engagement with Biofeedback and NAFLD/NASH in Chronic Kidney Patients
|
Apr 29, 2023 |
|
S4-E18.2 - Risk Stratification and Identification of NAFLD/NASH Patients in the Endocrinology Setting
|
Apr 29, 2023 |
|
S4-E18.1 - Meeting Cyrielle Caussy at the Intersection of Endocrinology and Hepatology
|
Apr 29, 2023 |
|
S4-E18 - Interplay of Endocrinology and Hepatology in Treatment and Knowledge Development
|
Apr 27, 2023 |
|
S4-E17.8 - Predictions for the Surfing NASH 6th Anniversary Special
|
Apr 23, 2023 |
|
S4-E17.7 - Discussing the Drug Development Landscape and Growing Community Education
|
Apr 23, 2023 |
|
S4-E17.6 - The Trajectory of Liver Science: How Far Have We Come?
|
Apr 22, 2023 |
|
S4-E17.5 - Surfer Throwbacks: Meeting the Co-Hosts for the First Time
|
Apr 22, 2023 |
|
S4-E17.4 - Stephen Harrison on Improving Clinical Trial Enrollment and Reminiscing on the Podcast’s Early Days
|
Apr 22, 2023 |
|
S4-E17.3 - Surfing NASH 3rd Anniversary Special: Interview with Frédéric Cren of Inventiva Pharma
|
Apr 21, 2023 |
|
S4-E17.2 - Surfing NASH 3rd Anniversary Special: Interview with Donna Cryer of the Global Liver Institute
|
Apr 21, 2023 |
|
S4-E17.1 - Surfing NASH 3rd Anniversary Special: Interview with Amy Articolo of Novo Nordisk
|
Apr 21, 2023 |
|
S4-E17 - Surfing the NASH Tsunami 3rd Anniversary Special
|
Apr 19, 2023 |
|
S4-E16.6 - From the Vault: #NASHDay 2022: SurfingNASH Wrap-Up
|
Apr 16, 2023 |
|
S4-E16.5 - How Do We Step Up to NASH?
|
Apr 16, 2023 |
|
S4-E16.4 - #NASHDay and Activating Awareness Across Communities
|
Apr 16, 2023 |
|
S4-E16.3 - The Untapped Potential of the Liver Community
|
Apr 15, 2023 |
|
S4-E16.2 - #NASHDay 2023 Theme: Step Up to NASH!
|
Apr 15, 2023 |
|
S4-E16.1 - What Makes This #NASHDay Different From Previous Years?
|
Apr 15, 2023 |
|
S4-E16 - Stepping Up to International #NASHDay 2023
|
Apr 13, 2023 |
|
S4-E15.5 - From the Vault: Advancing NASH Best Practices In NITs: “Stacking” NASH Biomarkers
|
Apr 09, 2023 |
|
S4-E15.4 - Final Takeaways from Liver Forum 14 and Reviewing the Published Slides
|
Apr 09, 2023 |
|
S4-E15.3 - Session VIII: Stretch Exercise: New Look at Statistics
|
Apr 08, 2023 |
|
S4-E15.2 - Liver Forum 14: Panelists Select Sessions of Interest
|
Apr 08, 2023 |
|
S4-E15.1 - What is The Liver Forum and Initial Impressions
|
Apr 08, 2023 |
|
S4-E15 - Review of Liver Forum 14
|
Apr 06, 2023 |
|
S4-E14.3 - Drug Development News: Phase 3 Press Releases on the Horizon
|
Apr 04, 2023 |
|
S4-E14.4 - International NASH Day 2023 and the Surfing NASH 3rd Anniversary
|
Apr 04, 2023 |
|
S4-E14.2 - NICE and FibroScan for Primary Care: Utilizing Early Detection to Prevent Cirrhosis
|
Apr 01, 2023 |
|
S4-E14.1 - Discussing the 3rd Annual Liver Connect Conference
|
Apr 01, 2023 |
|
S4-E14 - Co-Host Roundtable on the Liver Connect Conference, FibroScan and Pathways, Therapeutic News and More
|
Mar 31, 2023 |
|
S4-E13.6 - From the Vault: Innovations in NAFLD Care Conference: What Is the Importance of Steatosis in Metabolic Health?
|
Mar 26, 2023 |
|
S4-E13.5 - INCBCN 2023: What Will Be Its Impact?
|
Mar 26, 2023 |
|
S4-E13.4 - INCBCN 2023: Not Your Average Conference
|
Mar 26, 2023 |
|
S4-E13.3 - Discussing the Day 2 Program of INCBCN in Barcelona
|
Mar 25, 2023 |
|
S4-E13.2 - Linking NAFLD and NASH to Cancer and Educating on Fatty Liver Screening
|
Mar 25, 2023 |
|
S4-E13.1 - Feedback from the Inaugural INCBCN and Setting the Stage for the 2023 Workshop
|
Mar 25, 2023 |
|
S4-E13 - Previewing the 2023 Innovations in NAFLD Care Workshop
|
Mar 23, 2023 |
|
S4-E12.6 - From the Vault: Building a Disease Model for NASH Prevalence: Key Challenges
|
Mar 19, 2023 |
|
S4-E12.5 - ICER Draft Report: Different Stakeholder Impacts
|
Mar 19, 2023 |
|
S4-E12.4 - Biopsy, Biomarkers and Assessing the Value and Pricing of New Medications
|
Mar 19, 2023 |
|
S4-E12.3 - Keeping Regulatory Pace with Field Advancements
|
Mar 18, 2023 |
|
S4-E12.2 - ICER Draft Report: Assessment of Disease Prevalence and Prospective Drug Efficacy
|
Mar 18, 2023 |
|
S4-E12.1 - Introducing the ICER Draft Report on Resmetirom and Obeticholic Acid for NASH
|
Mar 18, 2023 |
|
S4-E12 - Deep Dive: ICER Draft Report on Resmetirom and Obeticholic Acid for NASH
|
Mar 16, 2023 |
|
S4-E11.6 - From the Vault: #NASHDay 2022 Preview: SurfingNASH Predictions
|
Mar 12, 2023 |
|
S4-E11.5 - Excitement and Trepidations: Exploring the Year Ahead in Fatty Liver
|
Mar 12, 2023 |
|
S4-E11.4 - Increasing Incidence of Type-2 Diabetes Among Adolescents
|
Mar 12, 2023 |
|
S4-E11.3 - Fighting for Fair Regulation Around What’s Deemed “Healthy”
|
Mar 11, 2023 |
|
S4-E11.1 - The Surfers Highlight What’s Happening for Fatty Liver in 2023
|
Mar 11, 2023 |
|
S4-E11.2 - Pricing Estimates for Imminent Drug Approvals and the Future Standard of NITs
|
Mar 11, 2023 |
|
S4-E11 - The Yin and Yang of Technology and Regulation
|
Mar 09, 2023 |
|
S4-E10.5 - From the Vault: 2022 Liver Conference: Pediatric NAFLD and Liver Health Education
|
Mar 05, 2023 |
|
S4-E10.4 - Pediatric and Adolescent Fatty Liver: Impact of Emerging Drugs and Trials
|
Mar 05, 2023 |
|
S4-E10.3 - Pediatric and Adolescent Fatty Liver: Implementing Real World Interventions
|
Mar 04, 2023 |
|
S4-E10.2 - Pediatric and Adolescent Fatty Liver: Cardiometabolic Complications and Challenges in NITs
|
Mar 04, 2023 |
|
S4-E10.1 - Increasing Incidence of Pediatric and Adolescent Fatty Liver
|
Mar 04, 2023 |
|
S4-E10 - Focus on Pediatric and Adolescent Fatty Liver Disease
|
Mar 02, 2023 |
|
S4-E9.5 - From the Vault: Discussing Comprehensive Care Models For NAFLD: Metrics, Key Performance Indicators and Improving Management
|
Feb 26, 2023 |
|
S4-E9.4 - Combating Swelling NAFLD and NASH Prevalence: Drugs, Diagnostics and Guidelines for the Frontline
|
Feb 26, 2023 |
|
S4-E9.3 - Diabetes Drug Choices With Benefits For NAFLD
|
Feb 25, 2023 |
|
S4-E9.2 - What’s Behind The New AACE Fatty Liver Guidelines?
|
Feb 25, 2023 |
|
S4-E9.1 - Growing NAFLD-Diabetes Dual Prevalence Increases CVD Risk for Diabetics
|
Feb 25, 2023 |
|
S4-E9 - From the Getting Ahead of the Rising Tide Series: Challenges as a Leading Patient Advocate is Screened
|
Feb 23, 2023 |
|
S4-E8.6 - From the Vault: Previewing Innovations in NAFLD Care 2022: Day Two Sessions
|
Feb 19, 2023 |
|
S4-E8.5 - The Future of Digital Therapeutics
|
Feb 19, 2023 |
|
S4-E8.4 - Digital Apps: Patient Participation and Regulatory Challenges
|
Feb 19, 2023 |
|
S4-E8.3 - Joe Rubinsztain on ChronWell and Scalable Technology
|
Feb 18, 2023 |
|
S4-E8.2 - Feasibility Study: Cognitive Behavior Therapy for Improved Liver Health
|
Feb 18, 2023 |
|
S4-E8.1 - Utilizing Prescription Digital Therapeutics to Combat Fatty Liver
|
Feb 18, 2023 |
|
S4-E8 - Focus on Digital Health with Better Therapeutics and ChronWell
|
Feb 16, 2023 |
|
S4-E7.6 - From the Vault: What’s next in Driving the Global Public Health Agenda for NAFLD?
|
Feb 12, 2023 |
|
S4-E7.5 - Introducing the Rising Tide Podcast and Closing Comments on AASLD Guidance
|
Feb 12, 2023 |
|
S4-E7.4 - AASLD Practice Guidance and Its Influence Outside of the US
|
Feb 12, 2023 |
|
S4-E7.3 - AASLD Guidance and the Practical Impact on Patients Today
|
Feb 11, 2023 |
|
S4-E7.2 - Discussing ALT Cut Off and Utilizing FIB-4 in Primary Care
|
Feb 11, 2023 |
|
S4-E7.1 - Introduction to the AASLD Practice Guidance: Impressions and Overview
|
Feb 11, 2023 |
|
S4-E7 - New 2023 AASLD Practice Guidance
|
Feb 09, 2023 |
|
S4-E6.5 - From the Vault: How NAFLD Patient Advocacy Works: Two Key Pieces
|
Feb 05, 2023 |
|
S4-E6.4 - Accessing New Drugs and the Future of Fatty Liver for Australians
|
Feb 05, 2023 |
|
S4-E6.3 - Linking Cardiovascular Outcomes to Fatty Liver and Utilizing FIB-4 in Australia
|
Feb 04, 2023 |
|
S4-E6.2 - Mapping Fatty Liver in Australia: Prevalence and Subpopulations
|
Feb 04, 2023 |
|
S4-E6.1 - Tony Rahman on Fatty Liver Prevalence in Australia
|
Feb 04, 2023 |
|
S4-E6 - Introduction to NAFLD and NASH in Australia
|
Feb 03, 2023 |
|
S4-E5.6 - From the VAULT: Patient Follow-Up Challenges in Modeling NASH Diagnostics
|
Jan 29, 2023 |
|
S4-E5.5 - Wrap-Up on Data Aggregation and Transparency, Patient Feedback and More
|
Jan 29, 2023 |
|
S4-E5.4 - Patient Data: Security Issues and Proactivity for Empowerment
|
Jan 29, 2023 |
|
S4-E5.3 - Predictive Health Intelligence: Exploring Areas of Application
|
Jan 28, 2023 |
|
S4-E5.2 - How the Predictive Health System Works: Algorithms and Economic Pressures
|
Jan 28, 2023 |
|
S4-E5.1 - Creating a "Combined Informatics and Clinical Program"
|
Jan 28, 2023 |
|
S4-E5 - Predictive Health Intelligence: Using Historic Blood Test Results to Identify Risk of Fatty Liver
|
Jan 26, 2023 |
|
S4-E4.6 - Donna Cryer on Aligning Regulatory Science and Expanding Avenues for Advocacy
|
Jan 22, 2023 |
|
S4-E4.5 - Patient Advocates on “Getting the Message Out” as Approval of Drugs Approaches
|
Jan 22, 2023 |
|
S4-E4.4 - NASH-TAG 2023: Emerging Optimism from a Watershed Moment
|
Jan 22, 2023 |
|
S4-E4.3 - Surfing NASH Community Interview with Caitlin Schneider of Sonic Incytes
|
Jan 21, 2023 |
|
S4-E4.2 - Surfing NASH Community Interview with Jerry Mabary of Chronwell
|
Jan 21, 2023 |
|
S4-E4.1 - Surfing NASH Community Interview with Pamela Danagher of Terns Pharmaceuticals
|
Jan 21, 2023 |
|
S4-E4 - Surfing NASH Audience Reacts to NASH-TAG and the Future of Fatty Liver
|
Jan 19, 2023 |
|
S4-E3.6 - Interview with Co-founder & CSO of HistoIndex, Dean Tai, on AI-Assisted Histology
|
Jan 15, 2023 |
|
S4-E3.5 - NASH-TAG Review: Donna Cryer on “Good Regulatory Science”
|
Jan 15, 2023 |
|
S4-E3.4 - NASH-TAG Review: Insights on the F3 Population and AI-Assistance for Improving Therapeutic Efficacy
|
Jan 15, 2023 |
|
S4-E3.3 - NASH-TAG Review: Unpacking Resmetirom Data and Drinking from a Firehose
|
Jan 14, 2023 |
|
S4-E3.2 - NASH-TAG Review: NITs, Clinical Trial Design and Addressing “Indeterminate Zones”
|
Jan 14, 2023 |
|
S4-E3.1 - NASH-TAG Review: Patient Advocate Panel on Influence of New Drugs and Interprofessional Collaboration
|
Jan 14, 2023 |
|
S4-E3 - NASH-TAG Wrap-Up: Therapeutic Efficacy of Resmetirom, NITs and Regulatory Science
|
Jan 12, 2023 |
|
S4-E2 - NASH-TAG 2023, Part 2: Friday and Saturday Takeaways and AI-Assisted Histologic Assessment
|
Jan 08, 2023 |
|
S4-E1 - NASH-TAG 2023, Part 1: Expansion in NIT Knowledge and How NASH Drug Development is Changing Patient Advocacy Today
|
Jan 07, 2023 |
|
S3-E63.3 - Year-End Interview with Ian Rowe
|
Jan 01, 2023 |
|
S3-E63.2 - Year-End Interview with Stephen Harrison
|
Dec 31, 2022 |
|
S3-E63.1 - Year-End Interview with Naim Alkhouri
|
Dec 30, 2022 |
|
S3-E63 - 2022 NAFLD Year-in-Review Interview Series, Part 3
|
Dec 29, 2022 |
|
S3-E62.3 - Year-End Interview with Jeff Lazarus
|
Dec 29, 2022 |
|
S3-E62.2 - Year-End Interview with Ken Cusi
|
Dec 28, 2022 |
|
S3-E62.1 - Year-End Interview with Mazen Noureddin
|
Dec 28, 2022 |
|
S3-E62 - 2022 NAFLD Year-in-Review Interview Series, Part 2
|
Dec 26, 2022 |
|
S3-E60.5 - Madrigal Announcement on Resmetirom: Combination Therapy and Closing Takeaways
|
Dec 26, 2022 |
|
S3-E60.4 - Madrigal Announcement on Resmetirom: Basic Science and Impact on Future Use of NITs
|
Dec 26, 2022 |
|
S3-E60.3 - Madrigal Announcement on Resmetirom: Diving into Implications
|
Dec 24, 2022 |
|
S3-E60.2 - Madrigal Announcement on Resmetirom: First Reactions and Differing Perspectives
|
Dec 24, 2022 |
|
S3-E60.1 - Donna Cryer on the Far-Reaching Implications of Madrigal’s Emerging Story on Resmetirom
|
Dec 24, 2022 |
|
S3-E61 - NASH-TAG 2023 Preview with Stephen Harrison
|
Dec 23, 2022 |
|
S3-E60 - Madrigal Announces Breaking News: Positive Topline Results from Pivotal MAESTRO-NASH Trial of Resmetirom
|
Dec 21, 2022 |
|
S3-E59.3 - Year-End Interview with Donna Cryer
|
Dec 18, 2022 |
|
S3- E59.2 - Year-End Interview with Hannes Hagström
|
Dec 17, 2022 |
|
S3-E59.1 - Year-End Interview with Scott Friedman
|
Dec 17, 2022 |
|
S3-E59 - 2022 NAFLD Year-in-Review Interview Series, Part 1
|
Dec 15, 2022 |
|
S3-58.5 - From the Vault: Part 2: Jörn Schattenberg, Louise Campbell and Roger Green discuss NAFLD and SurfingNASH.com
|
Dec 11, 2022 |
|
S3-58.4 - From the Vault: Part 1: Jörn Schattenberg, Louise Campbell and Roger Green discuss NAFLD and SurfingNASH.com
|
Dec 11, 2022 |
|
S3-E58.3 - NAIL-NIT Retrospective Analysis and the Role of Consortia in Reshaping the Focus of NITs
|
Dec 10, 2022 |
|
S3-E58.2 - Expanding Benefits in FibroScan Use and Integrating Digital Tools
|
Dec 10, 2022 |
|
S3-E58.1 - Returning to In-Person Meetings and Emerging News on NICE and FibroScan
|
Dec 10, 2022 |
|
S3-E58 - Surfing 2022: NAFLD Year-in-Review
|
Dec 08, 2022 |
|
S3-E57.5 - From the Vault: “Seeing what Should Be” – Imaging the Liver To Assess Functioning Hepatocytes
|
Dec 04, 2022 |
|
S3-E57.4 - Discussing Critical Success Factors for Placebo Cohorts
|
Dec 04, 2022 |
|
S3-E57.3 - A Priori Placebo Response Rates and Challenges in Managing Samples Through Trials
|
Dec 03, 2022 |
|
S3-E57.2 - Origins of the Liver Forum and Capturing the Richness of Data Emerging from NASH Studies
|
Dec 03, 2022 |
|
S3-E57.1 - Veronica Miller on Traversing from the HIV Forum to the Liver Forum
|
Dec 03, 2022 |
|
S3-E57 - The Liver Forum: Fighting Fatty Liver Using Collective Knowledge and Experience
|
Dec 01, 2022 |
|
S3-E56.6 - From the Vault: Focus On NASH Cirrhosis: Trials in Process and a Plea For MRE
|
Nov 27, 2022 |
|
S3-E56.5 - Improving Patient Self-Management and Key Takeaways on Nutrition for NASH Resolution
|
Nov 27, 2022 |
|
S3-E56.4 - Integrated Solutions for Improved Patient Support
|
Nov 27, 2022 |
|
S3-E56.3 - The Psychology of Decision-Making Around Diet and Professional Support
|
Nov 26, 2022 |
|
S3-E56.2 - Setting and Driving Realistic Goals, and Dietician Visits as a Life-Long Therapy
|
Nov 26, 2022 |
|
S3-E56.1 - Weight Reduction for NASH Resolution: Strategies for Long-Term Adherence to Lifestyle Modifications
|
Nov 26, 2022 |
|
S3-E56 - Focus on the Intersection of Nutrition and NASH
|
Nov 24, 2022 |
|
S3-E55.6 - From the Vault: #NASHDay 2022 Wrap-Up Panel: The Importance of #StopNASHNow
|
Nov 20, 2022 |
|
S3-E55.5 - Pediatric and Lean NASH: Learning from Diverse Populations
|
Nov 20, 2022 |
|
S3-E55.4 - Emerging Roles for ELF Test and Advances in Use of PPARs
|
Nov 20, 2022 |
|
S3-E55.3 - NIT Efficacy in Primary Care and Diabetes Clinic Settings
|
Nov 19, 2022 |
|
S3-E55.2 - Comparing Global Health Systems, Standardizing AST and Educating on NAFLD Prevalence
|
Nov 19, 2022 |
|
S3-E55.1 - Insights from Fatty Liver Foundation’s Annual Survey of Patient Perspectives
|
Nov 19, 2022 |
|
S3-E55 - 2022 AASLD Wrap-Up: Reviewing a Momentous Meeting
|
Nov 17, 2022 |
|
S3-E54.4 - An Interview with Michael Cooreman, CMO of Inventiva
|
Nov 13, 2022 |
|
S3-E54.3 - Exploring Mitochondrial Uncouplers in NASH and a Reanalysis of REGENERATE Study's Phase 3 Results
|
Nov 13, 2022 |
|
S3-E54.2 - Presentation on Efruxifermin in NASH with Fibrosis
|
Nov 13, 2022 |
|
S3-E54.1 - Utilizing Best Practices in Diagnostics
|
Nov 13, 2022 |
|
S3-E53.3 - Pan-Society Presentation of NAFLD Nomenclature Consensus Process
|
Nov 12, 2022 |
|
S3-E53.2 - Serum Metabolomics, Gene Therapy and the Waning Future of Biopsy
|
Nov 12, 2022 |
|
S3-E53.1 - The Gut Microbiome and Complexities of NAFLD
|
Nov 12, 2022 |
|
S3-E54 - AASLD 2022 Liver Meeting Live Coverage: Part 2
|
Nov 10, 2022 |
|
S3-E53 - AASLD 2022 Liver Meeting Live Coverage: Part 1
|
Nov 07, 2022 |
|
S3-E52.6 - From the Vault: AASLD 2021: The Path To Making NITs the “Gold Standard” for Drug Trials
|
Nov 06, 2022 |
|
S3-E52.5 - 2022 AASLD Preview: Final Thoughts
|
Nov 06, 2022 |
|
S3-E52.4 - Exploring the NAFLD-Metabolic Link Through Screening Tools
|
Nov 06, 2022 |
|
S3-E52.3 - Remote Wellness Tools and Disease Management
|
Nov 05, 2022 |
|
S3-E52.2 - Efficacy of NITs and Predictive Outcomes
|
Nov 05, 2022 |
|
S3-E52.1 - FIB-4 and the Way Forward in Primary Care Screening
|
Nov 05, 2022 |
|
S3-E52 - Part 2: A Preview of the 2022 AASLD Liver Meeting
|
Nov 03, 2022 |
|
S3-E51.5 - From the Vault: AASLD 2021 Wrap-up
|
Oct 30, 2022 |
|
S3-E51.4 - Discussing the NAFLD-Cancer Link and Fatty Liver Awareness
|
Oct 30, 2022 |
|
S3-E51.3 - AASLD 2022: A Preview of Patient Advocate Coverage on Liver Health Equity
|
Oct 29, 2022 |
|
S3-E51.2 - Fibrosis Progression Rates for Diabetic vs. Non-Diabetic Patients
|
Oct 29, 2022 |
|
S3-E51.1 - Preview of MAESTRO-NASH Results: a 2,000-Patient Phase 3 Trial
|
Oct 29, 2022 |
|
S3-E51 - A Preview of the 2022 AASLD Liver Meeting
|
Oct 27, 2022 |
|
S3-E50.6 - From the Vault: Digital Health and Patient Empowerment: a Conversation with Dr. Marcus Ranney
|
Oct 23, 2022 |
|
S3-E50.5 - FIB-4 as a Front-Line Tool for Primary Care Triage
|
Oct 23, 2022 |
|
S3-E50.4 - Economics and Challenges of Pathway Design
|
Oct 23, 2022 |
|
S3-E50.3 - Patient Input for Clinical Care Pathways and Guidelines
|
Oct 22, 2022 |
|
S3-E50.2 - The Future of Digital Therapeutics and Patient Wellness Tools
|
Oct 22, 2022 |
|
S3-E50.1 - Patient Needs and Inputs for Trial Design
|
Oct 22, 2022 |
|
S3-E50 - Focus on Patient Advocacy
|
Oct 20, 2022 |
|
S3-E49.5 - From the Vault: The NICE Draft Guidance vs. The Economics of NAFLD: A Bad Fit
|
Oct 16, 2022 |
|
S3-E49.4 - Delivering Meaningful Liver Test Results to Patients
|
Oct 16, 2022 |
|
S3-E49.3 - Linking Liver Outcomes and Socioeconomic Status
|
Oct 15, 2022 |
|
S3-E49.2 - Cancer vs Liver Disease Management: Political Pressures and Metaphorical Issues
|
Oct 15, 2022 |
|
S3-E49.1 - NICE on FibroScan for Primary Care
|
Oct 15, 2022 |
|
S3-E49 - NICE and VCTE Use in Community Settings
|
Oct 13, 2022 |
|
S3-E48.6 - From the Vault: Themes From NASH-TAG 2022: Insights on Combination Therapies
|
Oct 09, 2022 |
|
S3-E48.5 - Phase 3 Results of the REVERSE Trial by Intercept
|
Oct 09, 2022 |
|
S3-E48.4 - Promising Interim Data from Axcella’s Phase 2B EMMPACT Study
|
Oct 09, 2022 |
|
S3-E48.3 - More Positive Phase 2B Results from Poxel
|
Oct 08, 2022 |
|
S3-E48.2 - Phase 2B 'Wow!' Results from Akero’s HARMONY Trial
|
Oct 08, 2022 |
|
S3-E48.1 - Results of Altimmune’s 12 week Phase 1B Study of Pemvidutide
|
Oct 08, 2022 |
|
S3-E48 - Review of Exciting Clinical Trial Press Releases
|
Oct 06, 2022 |
|
S3-E47.6 - From the Vault: Most important Story of Summer: Ian Rowe says “FDA ELF Approval”
|
Oct 02, 2022 |
|
S3-E47.5 - Combination NIT Biomarkers and Developing a Viable System for Treating Patients
|
Oct 02, 2022 |
|
S3-E47.4 - Potential Bottlenecks in Getting Drugs to NAFLD Patients
|
Oct 02, 2022 |
|
S3-E47.3 - Implications of Positive Drug Trials and Eventual Approvals on NAFLD Treatment
|
Oct 01, 2022 |
|
S3-E47.2 - The role of multiple biomarker tests in the diagnostic process
|
Oct 01, 2022 |
|
S3-E47.1 - Collaborative energies shifting the force around Fatty Liver
|
Oct 01, 2022 |
|
S3-E47 - What does the next year hold for the NAFLD-metabolic disease link?
|
Sep 29, 2022 |
|
S3-E46.6 - From the Vault: Can Weight Loss From GLP-1s or Double/Triple Agonists Emulate the Effects of Bariatric Surgery in SPLENDOR?
|
Sep 25, 2022 |
|
S3-E46.5 - Discussing NITs and Final Thoughts on NAFLD Summit
|
Sep 25, 2022 |
|
S3-E46.4 - Weight Change and Lifestyle Modification in Clinical Trials
|
Sep 25, 2022 |
|
S3 E46.3 - Discussing Clinical Trial Design at the NAFLD Summit
|
Sep 24, 2022 |
|
S3-E46.2 - NAFLD Summit in Context and Learning from Failed Trials
|
Sep 24, 2022 |
|
S3-E46.1 - Underreported Alcohol Use and Treating Comorbidities
|
Sep 24, 2022 |
|
S3-E46 - A Review of the 2022 NAFLD Summit from Dublin
|
Sep 22, 2022 |
|
S3-E45.5 - From the Vault: What Can NAIL-NIT Retrospective Analysis Tell Us About NASH?
|
Sep 20, 2022 |
|
S3-E45.4 - Paris Review: NITs, Metabolic Disease and Final Thoughts
|
Sep 19, 2022 |
|
S3-E45.3 - Paris Review: Session 5 on Clinical Trial Innovation
|
Sep 19, 2022 |
|
S3-E45.2 - Paris Review: Opening and Closing Sessions
|
Sep 19, 2022 |
|
S3 E45.1 - Paris Review: Regulator Response and "Dynamic Tension”
|
Sep 19, 2022 |
|
S3-E45 - A Review of Paris NASH 2022 with Jeff McIntyre
|
Sep 15, 2022 |
|
S3-E44.6 - From Inside the Vault: Connecting the Dots at Paris NASH 2021
|
Sep 11, 2022 |
|
S3-E44.5 - Roger Green and Jeff Lazarus Discuss on NAFLD Summit
|
Sep 11, 2022 |
|
S3-E44.4 - Roger Green and Jeff Lazarus discuss NAFLD Nomenclature Conference and COVID-19
|
Sep 11, 2022 |
|
S3-E44.3 - Anticipating the Aftermath: Previewing Outcomes of Paris NASH
|
Sep 10, 2022 |
|
S3-E44.2 - Highlights from Paris NASH and an Integrated Multi-Specialty Approach
|
Sep 10, 2022 |
|
S3-E44.1 - Paris NASH Meeting Preview: Program Highlights on Metabolics
|
Sep 10, 2022 |
|
S3-E44 - A Preview of Paris NASH and NAFLD Summit 2022
|
Sep 08, 2022 |
|
From the Vault: Future NASH Drug Development: More Diverse Trial Populations and More Study of Combination NASH Drugs
|
Sep 04, 2022 |
|
S3-E43.5 - The Future of Combination Agents in NASH Therapy
|
Sep 04, 2022 |
|
S3-E43.4 - Optimizing Combination Agents
|
Sep 04, 2022 |
|
S3-E43.3 - Science Partnerships and NASH Trials
|
Sep 03, 2022 |
|
S3-E43.2 - Finding the Right Combinations in NASH Therapy
|
Sep 03, 2022 |
|
S3-E43.1 - Combination Agents for Fibrotic Regression
|
Sep 03, 2022 |
|
S3-E43 - Combination Agents: a Cornerstone Of Future NASH Therapy?
|
Sep 01, 2022 |
|
S3-E42.5 - From the Vault: NASH Patient Care and the Value of Patient Education
|
Aug 28, 2022 |
|
S3-E42.4 - Allied Health and Patient Empowerment for NAFLD
|
Aug 28, 2022 |
|
S3-E42.3 - Allied Health and Patient Empowerment for NAFLD
|
Aug 27, 2022 |
|
S3-E42.2 - Allied Health and Patient Empowerment for NAFLD
|
Aug 27, 2022 |
|
S3-E42.1 - Allied Health and Patient Empowerment for NAFLD
|
Aug 27, 2022 |
|
S3-E42 — Allied Health and Patient Empowerment for NAFLD
|
Aug 25, 2022 |
|
S3-E41.6 - From the Vault: Why NASH Drug Trials Fail
|
Aug 21, 2022 |
|
S3-E41.5 - Improving NASH Clinical Trials By Reducing Screen Fail Rates
|
Aug 21, 2022 |
|
S3-E41.4 - Improving NASH Clinical Trials By Reducing Screen Fail Rates
|
Aug 21, 2022 |
|
S3-E41.3 - Improving NASH Clinical Trials By Reducing Screen Fail Rates
|
Aug 20, 2022 |
|
S3-E41.2 - Improving NASH Clinical Trials By Reducing Screen Fail Rates
|
Aug 20, 2022 |
|
S3-E41.1 - Improving NASH Clinical Trials By Reducing Screen Fail Rates
|
Aug 20, 2022 |
|
S3-E41- Improving NASH Clinical Trials By Reducing Screen Fail Rates
|
Aug 18, 2022 |
|
S3-E40.5 - From the Vault: Why Cirrhosis Matters In Clinical Trial Strategy
|
Aug 14, 2022 |
|
S3-E40.4 - Challenges of Alcohol Screening in Fatty Liver Disease
|
Aug 14, 2022 |
|
S3-E40.3 - Importance of Early Diagnosis in Lean NASH
|
Aug 14, 2022 |
|
S3-E40.2 - A Simple Diagnostic Algorithm for Lean NASH
|
Aug 13, 2022 |
|
S3-E40.1 - Best Practices in Lean NASH: How the Article Came About
|
Aug 13, 2022 |
|
S3-E40 - Best Practices in Lean NASH -- Authors Provide Back Story
|
Aug 11, 2022 |
|
S3-E39.5 - From The Vault: Early, Accurate Patient Information Matters
|
Aug 07, 2022 |
|
S3-E39.4 - Patient Follow-Up Challenges in Modeling NASH Diagnostics
|
Aug 07, 2022 |
|
S3-E39.3 - NASH challenges: Early Diagnosis and NASH Patient Management
|
Aug 06, 2022 |
|
S3-E39.2 - What An Early Decision Models Tells Us About Fibrosis & Metabolic Diseases
|
Aug 06, 2022 |
|
S3-E39.1 - Creating An Early Diagnosis NASH Decision Model
|
Aug 06, 2022 |
|
S3-E39 - Reviewing a Decision Model for Early NASH Diagnosis
|
Aug 04, 2022 |
|
S3-E38.8 - From the Vault: Discussing Patient empowerment at INCBCN 2022
|
Jul 31, 2022 |
|
S3-E38.7 - From the Vault: How Ballooned hepatocyte Reads Affect NASH Clinical Trials
|
Jul 31, 2022 |
|
S3-E38.6 - From the Vault: Patient-Focused Drug Development from Global Liver Institute
|
Jul 31, 2022 |
|
S3-E38.5 - From the Vault: NAIL-NIT tackles NAS Score Challenges
|
Jul 30, 2022 |
|
S3-E38.4 - From the Vault: NITs & Advancing NASH Therapy at AASLD 2021
|
Jul 30, 2022 |
|
S3-E38.3 - From the Vault: Learning About Stellate Cells and Fibrosis at Paris NASH
|
Jul 30, 2022 |
|
S3-E38.2 - From the Vault: Scott Friedman on Fibrosis and Precision Medicine
|
Jul 30, 2022 |
|
S3-E38.1 - From the Vault: Why NASH Drug Trials Fail
|
Jul 29, 2022 |
|
S3-E38 - SurfingNASH 2nd Anniversary: Buzzsprout, Download Barriers and More!
|
Jul 28, 2022 |
|
S3-E37.5 - The Need to Focus on NASH Cirrhosis Patients
|
Jul 24, 2022 |
|
S3-E37.4 - The "Pincer Movement" In Cirrhosis Technology: Patient Support vs High-End MedTech
|
Jul 24, 2022 |
|
S3-E37.3 - Where Is The Next Cirrhosis Breakthrough?
|
Jul 23, 2022 |
|
S3-E37.2 - Can Today's Medicines Cause Fibrosis Regression in Cirrhosis Patients?
|
Jul 23, 2022 |
|
S3-E37.1 - Cirrhosis Screening & Diagnostic Tests
|
Jul 23, 2022 |
|
S3-E37 - What Do We Know That Can Help NASH Cirrhosis Patients Today?
|
Jul 21, 2022 |
|
S3-E36.5 - REGENERATE Redux: Clearing The Finish Line?
|
Jul 17, 2022 |
|
S3-E36.4 - REGENERATE Redux: Other Obeticholic Acid (OCA) Questions
|
Jul 17, 2022 |
|
S3-E36.3 - REGENERATE Redux: Safety and Tolerability With Obeticholic Acid
|
Jul 16, 2022 |
|
S3-E36.2 - REGENERATE Redux: What OCA Efficacy Results Mean For Patients
|
Jul 16, 2022 |
|
S3-E36.1 - REGENERATE Redux: Obeticholic Acid (OCA) Efficacy
|
Jul 16, 2022 |
|
S3-E36 - REGENERATE Redux - Can OCA Succeed With New Data?
|
Jul 14, 2022 |
|
S3-E35.5 - Liver Science At #ILC2022: Mid-Range Impact of Advances
|
Jul 10, 2022 |
|
S3-E35.4 - Liver Science At #ILC2022: Commercial Benefits From the New Liver Science
|
Jul 10, 2022 |
|
S3-E35.3 - Liver Science At #ILC2022: Stellate Cells, Omics and Novel Receptor Targets
|
Jul 09, 2022 |
|
S3-E35.2 - Liver Science At #ILC2022: The Interplay of Stellate Cell Dynamics and Hepatic Fibrosis
|
Jul 09, 2022 |
|
S3-E35.1 - Liver Science at #ILC2022: Circadian Rhythm and Stellate Cells
|
Jul 09, 2022 |
|
S3-E35 - #ILC2022 Look Back: Liver Science and Fibrosis
|
Jul 07, 2022 |
|
S3-E32.3 - #ILC2022 Looking Back: NASH Is a Complex Disease
|
Jul 04, 2022 |
|
S3-E32.2 - #ILC2022 Looking Back: NAFLD and Quality-of-Life
|
Jul 04, 2022 |
|
S3-E32.1 - #ILC2022 Looking Back: Patient Motivation and Systems Incentives
|
Jul 04, 2022 |
|
S3-E34.4 - #ILC2022 looking back: Crystal Balling and The Semaglutide Trial
|
Jul 03, 2022 |
|
S3-E33.2 - #ILC2022 Looking Back: Patient Engagement 2 -- Patient Communication
|
Jul 03, 2022 |
|
S3-E33.1 - #ILC2022 Looking Back: Patient Engagement 1 -- Nurses and Touchy Topics
|
Jul 03, 2022 |
|
S3-E34.3 - #ILC2022 Looking Back: Early Pemvidutide Results and a Little More on FIB-4
|
Jul 02, 2022 |
|
S3-E34.2 - #ILC2022 Looking Back: Other Thoughts on Resmetirom Presentations
|
Jul 02, 2022 |
|
S3-E34.1 - #ILC2022 Looking Back: Resmetirom Late-Breaker and Cirrhosis Study
|
Jul 02, 2022 |
|
S3-E34 #ILC2022 Wrap-Up 1: NASH Drug Development Excitement!
|
Jun 30, 2022 |
|
S3-E33 - Day 4 of ILC2022: Friendly Debates About NITs, PLUS Discussing the Patient Advocate's Perspective
|
Jun 27, 2022 |
|
S3-E32 - Days 1-3 of ILC 2022: The Value of FIB-4 and In-Person Meetings
|
Jun 26, 2022 |
|
S3-E30.4 - Highlighting Intriguing #ILC2022 Abstracts: Potential Uses of FIB-4
|
Jun 19, 2022 |
|
S3-E30.3 - Highlighting Intriguing #ILC2022 Abstracts: More on NAFLD Quality of Life
|
Jun 19, 2022 |
|
S3-E30.2 - Highlighting Intriguing #ILC2022 Abstracts: Elastography and the Importance of NAFLD Quality-of-Life Metrics
|
Jun 18, 2022 |
|
S3-E30.1 - Highlighting Intriguing #ILC2022 Abstracts: Machine Learning Identified NASH Biomarkers and a Cost-Effectiveness Study
|
Jun 18, 2022 |
|
S3-E30 - Previewing #ILC2022: Focus on NITs and Patients
|
Jun 16, 2022 |
|
S3-E29.2 - #NASHDay 2022 Wrap-Up Panel: The Importance of #StopNASHNow
|
Jun 12, 2022 |
|
S3-E29.1 - #NASHDay 2022 Wrap-up Panel: What #NASHDay Means To Our Community In 2022 and Why It Matters
|
Jun 12, 2022 |
|
S3-E28.4 - #NASHDay 2022 Preview: SurfingNASH Predictions
|
Jun 12, 2022 |
|
S3-E28.3 - #NASHDay 2022 Preview: Exciting NASH Community Collaboration and How It Drives Us Forward
|
Jun 11, 2022 |
|
S3-E28.2 - #NASHDay 2022 Preview: What New Approaches To Clinical Trial Design Will Mean For Our Community
|
Jun 11, 2022 |
|
S3-E28.1 - #NASHDay 2022 Preview: New Approaches To Clinical Trial Design
|
Jun 11, 2022 |
|
S3-E29 - #NASHDay 2022: SurfingNASH Wrap-up
|
Jun 10, 2022 |
|
S3-E28 - Previewing #NASHDay 2022: Patient Advocacy Thrives!
|
Jun 09, 2022 |
|
S3-E27.6 - 5th Global NASH Congress Wrap-Up: Dual Weight Loss Agonists, Expanded Imaging and the Implications for NAFLD
|
Jun 05, 2022 |
|
S3-E27.5 - 5th Global NASH Congress Wrap-Up: NAFLD Screening in Primary Care Practices With The GRIP Program
|
Jun 05, 2022 |
|
S3-E27.4 - 5th Global NASH Congress Wrap-Up: An Interview with Becky Taub
|
Jun 05, 2022 |
|
S3-E27.3 - 5th Global NASH Congress Wrap-Up: Key NAFLD Topics In The Room
|
Jun 04, 2022 |
|
S3-E27.2 - 5th Global NASH Congress Wrap-Up: Quality-of-Life and Portable Liver Scans
|
Jun 04, 2022 |
|
S3-E27.1 - 5th Global NASH Congress Wrap-Up: Fatty Liver Science and Patient Advocacy
|
Jun 04, 2022 |
|
S3-E27 - 5th Global NASH Congress Wrap-Up: Highlights & Speaker Interviews
|
Jun 02, 2022 |
|
S3-E26.4 - Advancing NASH Best Practices In NITs: Answering Questions, Next Steps
|
May 29, 2022 |
|
S3-E26.3 - Advancing NASH Best Practices In NITs: Optimizing a NASH Biomarker Set
|
May 29, 2022 |
|
S3-E26.2 - Advancing NASH Best Practices In NITs: "Stacking" NASH Biomarkers
|
May 28, 2022 |
|
S3-E26.1 - Advancing NASH Best Practices In NITs: Quentin Anstee's Five Key Takeaways
|
May 28, 2022 |
|
S3-E26 - What Are We Learning About Clinical Trial Best Practices For NITs?
|
May 26, 2022 |
|
S3-E25.6 - Emerging Concepts In NASH: NAFLD Patient Screening, NASH Management
|
May 22, 2022 |
|
S3-E25.5 - Emerging Concepts in NASH: Fatty Liver Pathophysiology, Epidemiology, Co-Morbidities
|
May 22, 2022 |
|
S3-E25.4 - NASH Drug Development in 2022: Will Quality of Life Data Help NASH Drugs Over the Finish Line?
|
May 22, 2022 |
|
S3-E25.3 - Future NASH Drug Development: More Diverse Trial Populations and More Study of Combination NASH Drugs
|
May 21, 2022 |
|
S3-E25.2 - NASH Drug Development In 2022: A Wealth of Data and a Promising NASH Pipeline
|
May 21, 2022 |
|
S3-E25.1 - NASH Drug Development in 2022: Late-Stage NASH Drugs and Their Path to Market
|
May 21, 2022 |
|
S3-E25 - Crystal Ball Looks at Drug Development and the NASH Pipeline
|
May 19, 2022 |
|
S3-E24.5 - From #INCBCN: Digital Health and Patient Empowerment: a Conversation with Dr. Marcus Ranney
|
May 15, 2022 |
|
3-E24.4 - Innovations in NAFLD Care Conference: What Is the Importance of Steatosis in Metabolic Health?
|
May 15, 2022 |
|
S3-E24.3 - Stakeholder Diversity at the Innovations in NAFLD Care 2022 Conference: a Critical Success Factor
|
May 15, 2022 |
|
S3-E24.2 - Controversy at the Innovations in NAFLD Care Conference: What Does Patient Empowerment Mean in Fatty Liver Disease?
|
May 14, 2022 |
|
S3-E24.1 - Did the Innovations in NAFLD Care Conference Strengthen the Case for an Integrated NAFLD Care Pathway?
|
May 14, 2022 |
|
S3-E24 - #INCBCN (Innovations in NAFLD Care 2022) Wrap-up plus Interview with Human Edge Founder Dr. Marcus Ranney
|
May 12, 2022 |
|
S3-E23.5 - How NAFLD Patient Advocacy Works: Two Key Pieces
|
May 08, 2022 |
|
S3-E23.4 - How NAFLD Patient Advocacy Works: Targets and Opportunities for the Fatty Liver Community
|
May 08, 2022 |
|
S3-E23.3 - How NAFLD Patient Advocacy Works: Disease Targets and Policy Successes in The Fatty Liver Community
|
May 07, 2022 |
|
S3-E23.2 - How NAFLD Patient Advocacy Works: Targets and Opportunities for the Fatty Liver Community
|
May 07, 2022 |
|
S3-E23.1 - NAFLD Patient Advocacy: Meet the Advocates And Hear Their Stories
|
May 07, 2022 |
|
S3-E23 - So How Does NAFLD Patient Advocacy Support the Entire Fatty Liver Community?
|
May 05, 2022 |
|
S3-E22.4 - Previewing the 5th Global NASH Congress: Summing Up
|
May 01, 2022 |
|
S3-E22.3 - Previewing the 5th Global NASH Congress: NASH Drug Development Presentations
|
May 01, 2022 |
|
S3-E22.2 - Previewing the 5th Global NASH Congress: What can We Learn About Drugs in Development From Hepatic Cell Models and Advanced Omics?
|
Apr 30, 2022 |
|
S3-E22.1 - Previewing the 5th Global NASH Congress: Gut Microbiome and Nutrition are the New Frontier
|
Apr 30, 2022 |
|
S3-E22 - NASH Tsunami previews the 5th Global NASH Congress
|
Apr 28, 2022 |
|
S3-E21.5 - NAFLD Provider education, NASH Patient Care and Digital Health
|
Apr 24, 2022 |
|
S3-E21.4 - Donna Cryer Discusses NCQA on NASH Quality and the New GLI "Liver Health is Public Health" campaign
|
Apr 24, 2022 |
|
S3-E21.3 - Digital Health and Behavioral Support apps in Future NASH Therapies
|
Apr 23, 2022 |
|
S3-E21.2 - NAFLD Incidence in All Americans and The NASH-Diabetes Link
|
Apr 23, 2022 |
|
S3-E21.1 - Challenges in NAFLD Care Delivery: Primary Care and NASH
|
Apr 23, 2022 |
|
S3-E21 - Naim Alkhouri and Donna Cryer Bring News to Surfing the NASH Tsunami
|
Apr 21, 2022 |
|
S3-E20 - Jörn Schattenberg, Louise and Roger discuss NAFLD and SurfingNASH.com
|
Apr 20, 2022 |
|
S3-E19.5 - NAIL-NIT: Expanding Vistas for Phase 1 Research
|
Apr 17, 2022 |
|
S3-E19.4 - NAIL-NIT: "Morphic Resonance" and FDA Test Criteria
|
Apr 17, 2022 |
|
S3-E19.3 - NAIL-NIT: What Naim Alkhouri and Jörn Schattenberg Plan for Retrospective Analysis
|
Apr 16, 2022 |
|
S3 - E19.2 - Beginnings And Core Principles In The Move Beyond the Biopsy
|
Apr 16, 2022 |
|
S3-E19.1 - Podcast News: SurfingNASH.com Is Here and a New Role for Jörn Schattenberg!
|
Apr 16, 2022 |
|
3-E19 - What Can NAIL-NIT Retrospective Analysis Tell Us About NASH Clinical Trials?
|
Apr 14, 2022 |
|
S3-E18.4 - Previewing Innovations in NAFLD Care 2022: Day Two Sessions
|
Apr 10, 2022 |
|
S3-E18.3 - Previewing Innovations in NAFLD Care 2022: SItes of Care and Organizing Patients
|
Apr 10, 2022 |
|
S3-E18.2 - Previewing Innovations in NAFLD Care 2022: NASH Epidemiology
|
Apr 09, 2022 |
|
S3-E18.1 - Why the Innovations in NAFLD Care Conference Came to Be
|
Apr 09, 2022 |
|
S3-E18 - Previewing The Innovations In NAFLD Care 2022 Conference
|
Apr 07, 2022 |
|
S3-E17.4 - What Can Single Cell Genomics Teach about Hepatic Regeneration?
|
Apr 03, 2022 |
|
S3-E17.3 - Spatial Transcriptomics and The History of Single Cell Genomics
|
Apr 03, 2022 |
|
S3-E17.2 - Future Targeted NASH Therapies and NASH Drug Development Today
|
Apr 02, 2022 |
|
S3-E17.1 - Potential Breakthrough in Anti-Fibrotic Therapies Through mRNA/CAR-T Combined Therapies
|
Apr 02, 2022 |
|
S3-E17 - New In NASH Science: CAR-T/mRNA Anti-Fibrotics and Advanced NASH omics
|
Mar 31, 2022 |
|
S3-E16.5 - Ready for "Prime Time?" - MRE and Hepatogram in NASH Clinical Practice
|
Mar 27, 2022 |
|
S3-E16.4 - What a Disease Model Suggests about the NASH Diagnostic Path
|
Mar 27, 2022 |
|
S3-E16.3 - What a Disease Model tells Us About NASH Patient Management
|
Mar 27, 2022 |
|
S3-E16.2 - What a NASH Disease Model Reveals About Treating Advanced Fibrosis
|
Mar 26, 2022 |
|
S3-E16.1 - Building a Disease Model for NASH Prevalence: Key Challenges
|
Mar 26, 2022 |
|
S3-E16 - The Prospective Role of Data Modeling in Diagnostic and Drug Development
|
Mar 24, 2022 |
|
S3-E15.4 - CLDF Liver Connect program: How Well Did It Work?
|
Mar 20, 2022 |
|
S3-E15.3 - From the 2022 Liver Conference: Pediatric NAFLD and Liver Health Education
|
Mar 20, 2022 |
|
S3-E15.1 - An Interview with CLDF President Zobair Younossi about Liver Connect
|
Mar 19, 2022 |
|
S3-E15.2 - Discussing Health Disparities at CLDF's NASH Connect Conference
|
Mar 18, 2022 |
|
S3-E15 - Discussing NAFLD and NASH at CLDF's 2nd Annual Liver Connect
|
Mar 17, 2022 |
|
S3-E14.5 - Improving Ballooned Hepatocyte Analysis Through Artificial Intelligence
|
Mar 14, 2022 |
|
S3-E14.4 - Ballooned Hepatocyte Analysis and Reassessing Drug Development
|
Mar 13, 2022 |
|
S3-E14.3 - Systematic Flaws in Semi-Quantitative Ballooned Hepatocyte Analysis
|
Mar 13, 2022 |
|
S3-E14.2 - Can We Manage Statistical Error in Ballooned Hepatocyte Analysis Better?
|
Mar 12, 2022 |
|
S3-E14.1 - How Ballooned Hepatocyte Analytics Weaken NASH Clinical Trials
|
Mar 12, 2022 |
|
S3-E14 - NAS Scores and the Challenge of Complex Ballooned Hepatocytes
|
Mar 10, 2022 |
|
S3-E13.4 - The NICE Draft Guidance vs. The Economics of NAFLD: Not a Great Fit
|
Mar 06, 2022 |
|
S3-E13.3 - NICE Draft Guidance on NAFLD Screening: Long Term Issues
|
Mar 06, 2022 |
|
S3-E13.2 - NICE Assesses FibroScan Screening: Health Economics & NAFLD
|
Mar 05, 2022 |
|
S3-E13.1 - NICE Assesses FibroScan Community Screening: Analytic Tensions
|
Mar 05, 2022 |
|
S3-E13 - Community Screening for NAFLD: What Must Advocates Prove?
|
Mar 03, 2022 |
|
S3 E12.4 - What Will Improve NASH Care For Black Americans Most and Fastest
|
Feb 27, 2022 |
|
S3-E12.3 - The Need: Enrich Black America's NASH Clinical Trials Share
|
Feb 27, 2022 |
|
S3-E12.2 - Why NASH Might Be Different For Black Americans: SDOH, Omics
|
Feb 26, 2022 |
|
S3-E12.1 - NASH Care for Non-Hispanic Black Americans: The Issues and Why They Matter
|
Feb 26, 2022 |
|
S3-E12 - Non-Hispanic Black Americans, SDOH and NASH
|
Feb 24, 2022 |
|
S3-E11.4 - NAIL-NIT: Retrospective Analysis, Then Prospective Studies
|
Feb 20, 2022 |
|
S3-E11.3 - NAIL-NIT and the Challenges of the NAS Score
|
Feb 20, 2022 |
|
S3-E11.2 - NAIL-NIT and the Challenges of Histopathology
|
Feb 19, 2022 |
|
S3-E11.1 - NAIL-NIT: The Thinking Behind a New NAFLD Consortium
|
Feb 19, 2022 |
|
S3-E11 - NAIL-NIT and the Path from Non-Invasive Testing To Outcomes
|
Feb 17, 2022 |
|
S3-E10.4 - Value of Screening for NAFLD as NASH Prevalence Grows
|
Feb 13, 2022 |
|
S3-E10.3 - Value of Early NASH Diagnosis as NAFLD Prevalence Grows
|
Feb 13, 2022 |
|
S3-E10.2 - What Does the SUNN Study Say About NASH Prevalence?
|
Feb 12, 2022 |
|
S3-E10.1 - NAFLD and NASH Prevalence and Advanced Liver Fibrosis in Germany
|
Feb 12, 2022 |
|
S3-E10 - Screening and Treatment Pathways in a World with High NAFLD Prevalence
|
Feb 10, 2022 |
|
S3-E9.4 - NASH Patient Care: The Value of Patient Education
|
Feb 06, 2022 |
|
S3-E9.3 - NASH Patient Education: Liver Nurses' Roles
|
Feb 06, 2022 |
|
S3-E9.2 - NASH Patient Support: Liver Nursing Challenges
|
Feb 05, 2022 |
|
S3-E9.1 - NASH Patient Support: Meet Today's Liver Nurses
|
Feb 05, 2022 |
|
S3-E9 - Are We Taking Full Advantage of the Skills and Knowledge that Liver Nurses and Advanced Nurse Practitioners Bring To NASH Education and Patient Care?
|
Feb 03, 2022 |
|
S3-E8.4 - SurfingNASH Discusses The Innovations In NAFLD Care 2022 Series With Jeff Lazarus And Jörn Schattenberg: Agenda Concepts
|
Jan 30, 2022 |
|
S3-E8.3 - SurfingNASH Discusses The Innovations In NAFLD Care 2022 Series With Jeff Lazarus And Jörn Schattenberg: Structural Healthcare Issues
|
Jan 30, 2022 |
|
S3-E8.2 - SurfingNASH discusses the Innovations in NAFLD Care 2022 Series with Jeff Lazarus and Jörn Schattenberg: Program Scope and Key Elements
|
Jan 29, 2022 |
|
S3 E8.1 - SurfingNASH Discusses The Innovations In NAFLD Care 2022 Series With Jeff Lazarus And Jörn Schattenberg: Program Objectives
|
Jan 29, 2022 |
|
S3-E8 - The "Innovations in NAFLD Care 2022" Series: Promoting the NAFLD Public Health Agenda
|
Jan 27, 2022 |
|
S3-E6 - Themes From NASH-TAG 2022: Insights on Combination Therapies
|
Jan 22, 2022 |
|
S3-E5 - NASH-TAG 2022 bonus: A conversation with Donna Cryer and Scott Friedman
|
Jan 21, 2022 |
|
S3-E4.4 - NASH-TAG 2022 Wrap-up: Improving Cost Efficiency of NASH Trials By Reducing Screen Fail Rates
|
Jan 16, 2022 |
|
S3-E4.3 - NASH-TAG 2022 Wrap-up: NITs from The FDA and Patients' Perspectives
|
Jan 16, 2022 |
|
S3-E4.2 - NASH-TAG 2022 Wrap-up: The Fireside Chat and the Changing Paradigm For NASH Diagnostics
|
Jan 15, 2022 |
|
S3-E4.1 - NASH-TAG 2022 Wrap-up: High Impact presentations
|
Jan 15, 2022 |
|
S3-E4 - NASH-TAG 2022 Wrap-up: What Did We Learn about Fatty Liver Disease and Clinical Trial Design?
|
Jan 13, 2022 |
|
S3-E3 - NASH-TAG 2022 Day Two: Weight loss, Innovative Approaches and the Fireside Chat on Testing Methods
|
Jan 09, 2022 |
|
S3-E2 - NASH-TAG 2022 Day 1 Summary: NASH Combination Therapies, Artificial Intelligence, Basic Science
|
Jan 09, 2022 |
|
S3-E1 - Previewing NASH-TAG 2022: Are we Ready To Pivot On Testing Methods like Histopathology?
|
Jan 05, 2022 |
|
S2-E64.3 - SurfingNASH's 2021 NAFLD Year-In-Review Covers The Growing Energy and Impact of NASH Patient Advocacy
|
Jan 02, 2022 |
|
S2-E64.2 - SurfingNASH's 2021 NAFLD Year-in-Review Covers the Emerging NAFLD Public Health Agenda
|
Jan 02, 2022 |
|
S2-E64.1 - SurfingNASH's 2021 NAFLD Year-in-Review Explores Key NASH Themes of the Year Plus the Growth of Our Podcast
|
Jan 01, 2022 |
|
S2-E64 - Stephen Harrison, Jeff Lazarus and Andrew Scott Join SurfingNASH.com's 2021 NAFLD Year-in-Review
|
Dec 31, 2021 |
|
S2-E63.3 - SurfingNASH's 2021 NAFLD year-in-review Covers NASH Cost Effectiveness and Quality-of-Life
|
Dec 30, 2021 |
|
S2-E63.2 - SurfingNASH's 2021 NAFLD year-in-review Covers NASH Multidisciplinary Initiatives and the Clinical Care Pathways Paper
|
Dec 29, 2021 |
|
S2-E63.1 - SurfingNASH's 2021 NAFLD year-in-review Covers Cirrhosis Treatment Strategies Today and NASH Drugs in Development
|
Dec 28, 2021 |
|
S2-E63 - Manal Abdelmalek, Ken Cusi And Jörn Schattenberg Join SurfingNASH's 2021 NAFLD Year-In-Review
|
Dec 27, 2021 |
|
S2-E62.3 - SurfingNASH's 2021 NAFLD year-in-review Covers the Patient-Advocate Initiated and Sponsored SUNN Study
|
Dec 26, 2021 |
|
S2-E62.2 - SurfingNASH's 2021 NAFLD year-in-review Covers MRE and the Broader View of Non-Invasive Liver Testing
|
Dec 24, 2021 |
|
S2-E62.1 - SurfingNASH's 2021 NAFLD year-in-review Covers AI in Histopathology
|
Dec 23, 2021 |
|
S2-E62 - Mazen Noureddin, Alina Allen And Wayne Eskridge Join SurfingNASH's 2021 NAFLD Year-in-Review
|
Dec 23, 2021 |
|
S2-E61.4 - How Might the Role of Bariatric Surgery Change post-SPLENDOR?
|
Dec 19, 2021 |
|
S2-E61.3 - Can Weight Loss From GLP-1s or Double/Triple Agonists Emulate the Effects of Bariatric Surgery in SPLENDOR?
|
Dec 19, 2021 |
|
S2-E61.2 - What does SPLENDOR Tell Us About the Impact of Bariatric surgery on Cardiovascular and Liver Events?
|
Dec 18, 2021 |
|
S2-E61.1 - What does SPLENDOR Tell Us About MACE and MALO?
|
Dec 18, 2021 |
|
SPLENDOR Study Lead Author Discusses The Effect Of Bariatric Surgery On MACE And MALO
|
Dec 16, 2021 |
|
S2-E60.3 - Previewing NASH-TAG 2022 Sessions 7-9 - Focus On Non-invasive Testing and Novel Targets
|
Dec 12, 2021 |
|
S2-E60.2 - Previewing NASH-TAG 2022 Sessions 4-6 - Focus On the Major Consortia and Artificial Intelligence
|
Dec 11, 2021 |
|
S2-E60.1 - Previewing NASH-TAG 2022 Sessions 1-3 -- Focus on Drug Development
|
Dec 11, 2021 |
|
S2-E60 - Explore Major Upcoming Events and Issues for NAFLD and NASH At Our NASH-TAG 2022 Preview
|
Dec 09, 2021 |
|
S2-E59.4 - What Can We Do To Reshape a Potentially Disasatrous Growth in Cirrhosis?
|
Dec 05, 2021 |
|
S2-E59.3 - What's next in Driving the Global Health Agenda for NAFLD?
|
Dec 05, 2021 |
|
S2-E59.2 - Key Issues For the NAFLD Global Health Agenda: Prevalence and Cost Data
|
Dec 04, 2021 |
|
S2-E59.1 - How the global Health Agenda for NAFLD Was Developed
|
Dec 04, 2021 |
|
S2-E59 - Discuss the Global NAFLD Agenda publication With Lead Author Jeffrey Lazarus
|
Dec 02, 2021 |
|
S2-E58.3 - Focus On NASH Cirrhosis: Trials in Process and a Plea For MRE
|
Nov 28, 2021 |
|
S2-E58.2 - Focus On NASH Cirrhosis: Reviewing FALCON 2 and the Belapectin Post Hoc Analysis of Phase 2 Data
|
Nov 27, 2021 |
|
S2-E58.1 - Focus On NASH Cirrhosis: Why Cirrhosis Matters and Review of REVERSE Results at AASLD
|
Nov 27, 2021 |
|
S2-E57.4 - TLMdX 2021 From AASLD: What Does the Future Hold For NAFLD and NASH?
|
Nov 22, 2021 |
|
S2-E57.3 - 2021 TLMdX From AASLD: Non-conventional efficacy Metrics, Genomics of NAFLD and an Exciting Future
|
Nov 21, 2021 |
|
S2-E57.2 - 2021 TLMdX From AASLD: The Path To Making NITs the "Gold Standard" for Drug Trials
|
Nov 21, 2021 |
|
S2-E57.1 - 2021 TLMdX from AASLD: Putting a "Big, Fat Dent" in NAFLD and NASH
|
Nov 21, 2021 |
|
S2-E57 - AASLD 2021 Wrap-up: Looking Back on an Eventful TLMdX
|
Nov 19, 2021 |
|
S2-E56 - Day Four at the 2021 TLMdX From AASLD
|
Nov 16, 2021 |
|
S2-E55 - Day Three at the 2021 TLMdX From AASLD
|
Nov 15, 2021 |
|
S2-E54.3 - Inside the Patient-Focused Drug Development Meeting: the Advocates' Priorities
|
Nov 13, 2021 |
|
S2-E54.2 - Inside the Patient-Focused Drug Development Meeting: the Advocates' Perspectives
|
Nov 13, 2021 |
|
S2-E54.1 - Inside the Patient-Focused Drug Development meeting: Stories of Personal Experiences
|
Nov 13, 2021 |
|
S2-E58 - What's New In Clinical Trials for NASH Cirrhosis
|
Nov 11, 2021 |
|
S2-E54 - Go Inside a Pivotal Event: the NASH Patient-Focused Drug Development Meeting
|
Nov 11, 2021 |
|
S2-E53.3 - AASLD 2021 Preview: NASH Patient Management Topics Range From Drugs In Development To Applied Day-to-Day Issues
|
Nov 07, 2021 |
|
S2-E57.1 - 2021 TLMdX from AASLD: Putting a "Big, Fat Dent" in NAFLD and NASH
|
Nov 07, 2021 |
|
S2-E53.2 - AASLD 2021 Preview: A Weekend of Broad NASH Disease/Drug Management Coverage
|
Nov 06, 2021 |
|
S2-E53.1 - AASLD 2021 Preview: Presentations on Basic NASH Science
|
Nov 06, 2021 |
|
S2-E53 - SurfingNASH Previews AASLD 2021: the Digital Liver Meeting
|
Nov 04, 2021 |
|
S2-E52.4 - MRE Findings Suggest Flaws in Fibrosis As Endpoint
|
Oct 31, 2021 |
|
S2-E52.3 - Can MRE Provide Reliable, Non-Invasive Clinical Trial Endpoints?
|
Oct 31, 2021 |
|
S2-E52.2 - How Liver Stiffness Measures Can Improve Practical Patient Management
|
Oct 30, 2021 |
|
S2-E52.1 - MRE Predicts Long-Term Progression and Outcomes in Chronic Liver Disease Patients
|
Oct 30, 2021 |
|
S2-E52 - Predicting Long-Term Outcomes Using MR Elastography
|
Oct 28, 2021 |
|
S2-E51.3 - More from Paris NASH: Overcoming Histopathology's flaws
|
Oct 24, 2021 |
|
S2-E51.2 - More from Paris NASH: Precision Medicine's role in Drug Development and Patient Diagnosis
|
Oct 23, 2021 |
|
S2-E51.1 - More from Paris NASH: precision Medicine, Stellate Cells and Hepatic Influencers
|
Oct 23, 2021 |
|
S2-E51 - Precision medicine, Fibrosis, Liver Function and the Future: a Discussion With Scott Friedman
|
Oct 21, 2021 |
|
S2-E50.3 - "Dare to Dream" - How New Imaging Methods Can Change Our Future
|
Oct 17, 2021 |
|
S2-E50.2 - "Seeing What Should Be" - Imaging the Liver To Assess Functioning Hepatocytes
|
Oct 16, 2021 |
|
S2-E50.1 - "Potential Game Changer" - Imaging Can Provide a Dynamic View of NASH Evolution
|
Oct 16, 2021 |
|
S2-E50 - "Dare to Dream" - the Exciting, Evolving World of Organ Imaging
|
Oct 14, 2021 |
|
S2-E49.3 - Clinical Care Pathway: What Can Be Done Today?
|
Oct 10, 2021 |
|
S2-E49.2 - Clinical Care Pathway: Behavior Change and Prevalence Data
|
Oct 09, 2021 |
|
S2-E49.1 - Clinical Care Pathway: How It Came To Be
|
Oct 09, 2021 |
|
S2-E49 - Finally, a Clinical Care Pathway For a Hidden Pandemic!
|
Oct 07, 2021 |
|
S2-E48.4 - Closing Thoughts On Summer: What Mattered Most?
|
Oct 03, 2021 |
|
S2-E48.3 - Closing thoughts on Summer: Looking From a Patient-Based Perspective
|
Oct 03, 2021 |
|
S2-E48.2 - Closing Thoughts On Summer: More on FGF-21s and A Topical "Hijacking"
|
Oct 02, 2021 |
|
S2-E48.1 - Closing Thoughts On Summer: Mazen Noureddin's Two Big Things
|
Oct 02, 2021 |
|
S2-E48 - Closing Thoughts On an Eventful NASH Summer
|
Sep 30, 2021 |
|
S2-E47.3 - Most Important Story of Summer? Manal Abdelmalek Says, "NIH Funding Liver Cirrhosis Network"
|
Sep 26, 2021 |
|
S2-E47.2 - Most Important Story of Summer? Michelle Long Says, "Harrison/Alkhouri Prevalence Paper."
|
Sep 25, 2021 |
|
S2-E47.1 - Most important Story of Summer? Ian Rowe says, "FDA ELF Approval."
|
Sep 25, 2021 |
|
S2-E47 - Ask Opinion Leaders: The Biggest NAFLD/NASH Stories of Summer
|
Sep 24, 2021 |
|
S2-E46.3 - Top Stories From Paris NASH: Connecting the Dots
|
Sep 19, 2021 |
|
S2-E46.1 - Top stories from Paris NASH: Epidemiology and Clinical Aspects
|
Sep 18, 2021 |
|
S2-E46.2 - Top Stories From Paris NASH: Deep Dive into Fibrosis
|
Sep 18, 2021 |
|
S2-E46 - Highlights from Paris NASH
|
Sep 16, 2021 |
|
S2-E45.3 - Discussing the EASL Guidelines and the Path to A Non-Invasive Testing Future with Donna Cryer
|
Sep 12, 2021 |
|
S2-E45.2 - Discussing Non-Invasive Testing and the Patient Experience with Wayne Eskridge.
|
Sep 11, 2021 |
|
S2-E45.1 - Discussing Fatty Liver Disease Prevalence And Patient Awareness With Anthony Villiotti
|
Sep 11, 2021 |
|
S2-E45 - Ask the Advocates: The Biggest NAFLD/NASH Story of the Summer
|
Sep 09, 2021 |
|
S2-E44.4 - COVID-19 and Fatty Liver - What Impact Will the Delta Variant Have On Clinical Trials?
|
Sep 05, 2021 |
|
S2-E44.3 - COVID-19 And Fatty Liver - Areas for Confusion and Policy Discord
|
Sep 05, 2021 |
|
S2-E44.2 - COVID-19 And Fatty Liver - Lessons from Immunocompromised Patients and Other Countries
|
Sep 04, 2021 |
|
S2-E44.1 - COVID-19 And Fatty Liver --How Immunocompromised and Transplant Patients Became A Priority for Booster Doses
|
Sep 04, 2021 |
|
S2-E44 - The impact Of the COVID-19 Delta Variant on NAFLD and NASH
|
Sep 02, 2021 |
|
S2-E43.4 -Rethinking Cirrhosis: A Call To Action
|
Aug 29, 2021 |
|
S2-E43.3 - Driving A Reconsideration Of Cirrhosis In Drug Development
|
Aug 29, 2021 |
|
S2-E43.2 - Rethinking Cirrhosis As A Target For Drug Development
|
Aug 28, 2021 |
|
S2-E43.1 - Cirrhosis - Challenges in Treating Patients
|
Aug 28, 2021 |
|
S2-E43 - Can Cirrhosis Drive Drug Development In NASH?
|
Aug 26, 2021 |
|
S2-E42.3 - Why FGFs Matter - Episode Opening and Closing, Plus a Question About Screen Fail Rates
|
Aug 22, 2021 |
|
S2-E42.2 - How FGFs Work In The Body And What This Means For NAFLD And NASH
|
Aug 21, 2021 |
|
S2-E42.1 - FGF drugs in Development - A Promising Class of Agents
|
Aug 21, 2021 |
|
S2-E42 - How Do Fibroblast Growth Factor (FGF) Drugs Work and Why Are They So Important?
|
Aug 19, 2021 |
|
S2-E41.4 - Reasons To Believe That a Multidisciplinary Fight Against NASH Will Bring Value
|
Aug 15, 2021 |
|
S2-E41.3 - Critical Success Factors In the Multidisciplinary Fight Against NASH
|
Aug 14, 2021 |
|
S2-E41.2 - Specialties and Organizations Unite to Fight the NASH Epidemic
|
Aug 14, 2021 |
|
S2-E41.1 - SPECIAL FEATURE: Interview with Louise Campbell
|
Aug 13, 2021 |
|
S2-E41 - Preparing for the NASH Epidemic: Behind a Multidisciplinary Call to Action
|
Aug 12, 2021 |
|
S2-E40.3 - Discussing Comprehensive Care Models For NAFLD - Metrics, Key Performance Indicators and Improving Management
|
Aug 08, 2021 |
|
S2-E40.2 - Discussing Comprehensive Care Models For NAFLD - Providers Respond
|
Aug 07, 2021 |
|
S2-E40.1 - Discussing Comprehensive Care Models for NAFLD - Jeff Lazarus Presents Research
|
Aug 07, 2021 |
|
S2-E40 - Discussing Comprehensive Care Models for NAFLD
|
Aug 05, 2021 |
|
S2-E39.3 - 20K Celebration Interview With Jörn Schattenberg and Ian Rowe
|
Aug 01, 2021 |
|
S2-E39.2 - 20K Celebration Interviews With Stephen Harrison and Naim Alkhouri
|
Jul 31, 2021 |
|
S2-E39.1 - 20K celebration Interview with Donna Cryer
|
Jul 31, 2021 |
|
S2-E39 - Celebrating Two Milestones for SurfingNASH!
|
Jul 29, 2021 |
|
S2-E38.3 - Creating an Ecosystem of Community Physicians To Support Clinical Trials
|
Jul 25, 2021 |
|
S2-E38.2 - Building a Culture That Encourages Patient Participation
|
Jul 24, 2021 |
|
S2-E38.1 - Motivating Underserved Patients to Participate in Clinical Trials
|
Jul 24, 2021 |
|
S2-E38 - Increasing Diversity in the Clinical Trial Patient Population
|
Jul 22, 2021 |
|
S2-E37.3 - Spreading the NASH Message Throughout the Broader Community Of Healthcare Practitioners
|
Jul 18, 2021 |
|
S2-E37.2 - NASH Diagnostics Provide a Natural Brake on Overly Broad Adoption of NASH Drugs
|
Jul 17, 2021 |
|
S2-E37.1 - Key Reasons the NASH Drug Market Will Evolve Differently From Statins
|
Jul 17, 2021 |
|
S2-E37 - Why the NASH Market Is Different From Statins
|
Jul 15, 2021 |
|
S2-E36.3 - From the #ILC2021 Wrap-up: Focus on Care Pathways and Treatment Roles
|
Jul 04, 2021 |
|
S2-E36.2 - From The #ILC2021 Wrap-Up: Focus On Drug Development
|
Jul 03, 2021 |
|
S2-E36.1 - From the #ILC2021 Wrap-up: Focus on Diagnostics
|
Jul 03, 2021 |
|
S2-E36 - #ILC2021 Wrap-Up: Big Issues, Key Takeaways, Remaining Issues
|
Jul 01, 2021 |
|
S2-E35 - #ILC2021 Day Four - Promising Times Ahead, Maybe With a Few More Bumps In the Road
|
Jun 26, 2021 |
|
S2-E34 - #ILC2021 Day Three - Multi-Disciplinary NAFLD Thinking, with Exciting Drugs on the Horizon
|
Jun 25, 2021 |
|
S2-E33 - #ILC2021 Day Two -- Learning About Patients Through Large Databases
|
Jun 24, 2021 |
|
S2-E32 - Leaders Provide Perspectives on #ILC2021
|
Jun 24, 2021 |
|
S2-E31.3 - Previewing Digital ILC 2021 -- Part II -- NITs, late-breakers and intriguing topics
|
Jun 20, 2021 |
|
S2-E31.2 - Previewing Digital ILC 2021 -- Part II -- Drug Development
|
Jun 19, 2021 |
|
S2-E31.1 - Previewing Digital ILC 2021 -- Part II -- "Favorite Things" and Discussing Metabolic issues
|
Jun 19, 2021 |
|
S2-E31 - DIgital ILC 2021 -- Preview II
|
Jun 17, 2021 |
|
S2-E30.3 - The Global Liver institute US NASH Action Plan - treatment and health system challenges
|
Jun 13, 2021 |
|
S2-E30.2 - The Global Liver Institute US NASH Action Plan - Common, Reliable Diagnostics Are Critical
|
Jun 12, 2021 |
|
S2-E30.1 - The Global Liver Institute US NASH Action Plan - Overview And What Education Must Achieve
|
Jun 12, 2021 |
|
S2-E30 - The Global Liver institute US NASH Action Plan - What It Is and How We All Can Help Support it
|
Jun 10, 2021 |
|
S2-E29.3 - Previewing Digital ILC 2021 -- Part 1 -- What might emerge?
|
Jun 06, 2021 |
|
S2-E29.2 - Previewing Digital ILC 2021 -- Part 1 -- Interests and Issues
|
Jun 05, 2021 |
|
S2-E29.1 - Previewing Digital ILC 2021 -- Part 1 -- Meeting Overview
|
Jun 05, 2021 |
|
S2-E29 - Previewing Digital ILC 2021 -- Part 1
|
Jun 03, 2021 |
|
S2-E27.2 - A Deeper Look At International NASH Day 2021 -- Activities, Future Plans, And Global Liver Institute Growth
|
May 29, 2021 |
|
S2-E27.1 - previewing International nASH day 2021 -- overview of events
|
May 29, 2021 |
|
S2 - E28 - SPECIAL EPISODE: What Can We Learn The Aldafermin Discontinuation In F2/F3 NASH?
|
May 27, 2021 |
|
S2-E27 - Previewing International NASH Day -- a growing Day of Global Education and Organizing
|
May 27, 2021 |
|
S2-E26.3 - How much will real-life NASH treatment decisions depend on the specialty of the prescriber?
|
May 23, 2021 |
|
S2-E26.2 - How simply "Vertebrate" will future NASH therapy be?
|
May 22, 2021 |
|
S2-E26.1 - What will NASH Pharmacotherapy Look Like When we have Multiple Options?
|
May 22, 2021 |
|
S2-E26 - What Will Treatment Pathways Look Like For NASH Patients?
|
May 20, 2021 |
|
S2-E25.1 (CORRECTED) - Prevalence of NAFLD and NASH 2021 -- Key Findings
|
May 17, 2021 |
|
S2-E25.2 (CORRECTED) - Prevalence of NAFLD and NASH 2021 -- Deeper Dive
|
May 17, 2021 |
|
S2-E25.3 (CORRECTED) - Prevalence of NAFLD and NASH 2021 -- An Urgent Call to Action
|
May 17, 2021 |
|
S2-E25 - How many Americans Are Living with NAFLD and NASH?
|
May 13, 2021 |
|
S2-E24.3 - From The Fourth Global NASH Congress -- How Diagnostics Will Evolve Over The Next Several Years
|
May 09, 2021 |
|
S2-E24.2 - From The Fourth Global NASH Congress -- How Treatment WIll Evolve Over The Next Several Years
|
May 08, 2021 |
|
S2-E24.1 - From the Fourth Global NASH Congress -- Changing Paradigms and Guidelines
|
May 08, 2021 |
|
S2-E24 - Fourth Global NASH Congress -- Wrapping Up
|
May 06, 2021 |
|
S2-E23.1 - From the Fourth Global NASH Congress -- Diagnosing Diagnostics
|
May 03, 2021 |
|
S2-E23 - Wrapping up Day Two of the Fourth Global NASH Congress -- Drugs, lifestyles and Health policy
|
May 01, 2021 |
|
S2-E22 - Day Two at the 4th Global NASH Congress -- many New Drugs and Non-Pharmacologic Interventions
|
Apr 30, 2021 |
|
S2-E21 - Day One At The 4th Global NASH Congress -- Diagnostics, Drugs And Regulatory Issues
|
Apr 29, 2021 |
|
S2-E20.3 - How Can we Best Use NASHmap in Clinical trials and Patient Treatment?
|
Apr 25, 2021 |
|
S2-E20.2 - What Can We Learn about NASH From NASHmap?
|
Apr 24, 2021 |
|
S2-E20 - 14-variable Machine Learning model identifies Probable NASH patients from Electronic Health Records
|
Apr 22, 2021 |
|
S2-E20.1 - How NASHmap, the 1st Machine Learning Model to Identify Probable NASH Patients, Came to Life
|
Apr 21, 2021 |
|
S2-E19.3 - Pharmacotherapy Themes At The 4th Global NASH Congress
|
Apr 18, 2021 |
|
S2-E19.2 - Patient-Centric Themes At The 4th Global NASH Congress
|
Apr 17, 2021 |
|
S2-E19.1 - Non-Invasive Testing Themes at the 4th Global NASH Congress
|
Apr 17, 2021 |
|
S2-E19 - Previewing the 4th Global NASH congress
|
Apr 15, 2021 |
|
S2 E18.3 -- Stephen Harrison and Alina Allen discuss what her work portends for future trials.
|
Apr 11, 2021 |
|
S2 E18.2 -- How Might We Treat Differently If We Knew Which Cirrhotic Patients Are Likely To Progress?
|
Apr 10, 2021 |
|
S2 E18.1 -- How Does MR Elastography Help Identify NASH PAtients Who Are Likely To Progress?
|
Apr 10, 2021 |
|
S2-E18 - Magnetic Resonance Elastography Predicts Prognosis for NASH patients
|
Apr 08, 2021 |
|
S2-E17.3 -- The value of ultrasound and the goals of patient screenin
|
Apr 04, 2021 |
|
S2-E17.2 — Modeling the relative impact of treating NASH vs. CVD in patients with different fibrosis levels
|
Apr 03, 2021 |
|
S2-E17.1 - Questions in Screening: Do Liquid Tests Bring Better Value than Elastography?
|
Apr 03, 2021 |
|
S2-E17 - New lessons from Leeds: Streamlining Non-Invasive Testing algorithms
|
Apr 01, 2021 |
|
S2-E16.3 - How NASH treatment Might Evolve as Therapies Come to Market
|
Mar 28, 2021 |
|
S2-E16.2 - Future Directions for NASH Cost-Effectiveness Research
|
Mar 27, 2021 |
|
S2 E16.1 -- How Cost-Effectiveness Research On Widespread NIT Screening In The U.S. Has Evolved
|
Mar 27, 2021 |
|
S2-E16 -- Cost-Effectiveness of Widespread Non-Invasive NASH Testing and Treatment
|
Mar 25, 2021 |
|
S2-E15 — Wrapping Up NASH-TAG 2021
|
Mar 18, 2021 |
|
S2-E14 - NASH-TAG Session 4 Summary: Basic Science and Promising Drugs on the Horizon
|
Mar 15, 2021 |
|
S2-E13 - NASH-TAG Session 3 Summary: Trial Designs of the Future and the Future of Diabetes Drugs in NASH
|
Mar 14, 2021 |
|
S2-E12 - NASH-TAG Session 2 Summary: Innovative Trial Design and Robust Histologic Analyses
|
Mar 13, 2021 |
|
S2 E11 — NASH-TAG Session 1 summary: Major Drugs in Development and Why Trials Fail
|
Mar 12, 2021 |
|
S2 E10 — Before NASH-TAG, Conversations With Co-Directors
|
Mar 11, 2021 |
|
S2-E9.2—Drug-Free Treatment of Early Fatty Liver Disease: Issues for Public Health
|
Mar 07, 2021 |
|
S2-E9.1—Drug-Free Treatment of Early Fatty Liver Disease: Identity matters
|
Mar 07, 2021 |
|
S2-E9.3 — Introducing LIVErHEALTHY: a program for patients with Early Fatty Liver disease
|
Mar 07, 2021 |
|
S2-E9 - Novel Approaches to Drug-Free Treatment of Early Fatty Liver Disease
|
Mar 04, 2021 |
|
S2-E8.3 - Previewing NASH-TAG 2021: Two intriguing side conversations
|
Feb 27, 2021 |
|
S2-E8.2 - Previewing NASH-TAG 2021: Day Two
|
Feb 27, 2021 |
|
S2-E8.1 - Previewing NASH-TAG 2021: Day One
|
Feb 27, 2021 |
|
S2-E8 - Previewing NASH-TAG 2021
|
Feb 25, 2021 |
|
S2-E7.3 - The newer diabetes drugs and NASH: Educating and Motivating Stakeholders
|
Feb 20, 2021 |
|
S2-E7.2 - The Newer Diabetes Drugs and NASH: How T2D Patients are likely to respond
|
Feb 20, 2021 |
|
S2-E7.1 - The Newer Diabetes Drugs and NASH: Modes of Action
|
Feb 20, 2021 |
|
S2-E7 - The Newer Diabetes Drugs and Patients with NASH
|
Feb 18, 2021 |
|
S2 E6.3 - #RealTalk: Trial Recruiting Challenges: Traps to Avoid in designing patient protocols for NASH Trials
|
Feb 14, 2021 |
|
S2 E6.2 - #RealTalk: Trial Recruiting Challenges: Educating Physician during the pandemic
|
Feb 13, 2021 |
|
S2 E6.1 - #RealTalk: Trial Recruiting Challenges: Daunting Numbers and Challenging Protocols
|
Feb 13, 2021 |
|
S2 E6 - #RealTalk on Clinical Trial Design and Execution
|
Feb 11, 2021 |
|
S2 E5.5 - Bonus Interview with Suneil Hosmane: What FDA webcast means for "Wet" Diagnostics
|
Feb 10, 2021 |
|
S2 E5.4 - Bonus Interview with Prof. Dr. Jörn M. Schattenberg: What FDA webcast means for researchers and trial sites outside the US
|
Feb 10, 2021 |
|
S2 E5.3 — After the FDA Webcast: Discussing Drug Development and Clinical Trial Strategies
|
Feb 09, 2021 |
|
S2 E5.2 — After the FDA Webcast: Discussing Clinical Endpoints
|
Feb 09, 2021 |
|
S2 E5.1 - After the FDA Webcast: Beginning and Ending Perceptions
|
Feb 08, 2021 |
|
S2 E4.2 - Anticipating The FDA Webcast: Specific Items to Listen For
|
Feb 04, 2021 |
|
S2 E4.1 - Anticipating the FDA Webcast: Overall Areas for Guidance
|
Feb 04, 2021 |
|
S2 E5 - What We Learned at Today's FDA Webcast on NASH Drug Development
|
Feb 01, 2021 |
|
S2 E4 - What to Listen For Friday at the FDA Webcast
|
Jan 28, 2021 |
|
S2 E3.2 - Call to action: Can We use COVID-19 Vaccine Centers to support Liver health?
|
Jan 23, 2021 |
|
S2 E3.1 - Challenges Disadvantaged Minorities Face in Liver Health
|
Jan 23, 2021 |
|
S2 E3 A Call to Action on MLK Day: Supporting disadvantaged Minorities in Managing Liver Health
|
Jan 21, 2021 |
|
S2 E2.3 - Partners and enablers Necessary to Help Drive Broader NAFLD and Non-Communicable Disease
|
Jan 16, 2021 |
|
S2 E2.2 - Economic and Patient Motivation Costs and Value of telemedicine and New Non-Invasive Diagnostic Testing
|
Jan 16, 2021 |
|
S2 E2.1 - Innovations in Telemedicine and Mobile Technology can improve care for NAFLD patients
|
Jan 16, 2021 |
|
S2 E2 — How COVID-19 is changing patient management and clinical trials
|
Jan 14, 2021 |
|
S2 E1.3 - Challenges and Big Ideas for NAFLD/NASH Patient Diagnosis and Treatment in the Post-Second Wave World
|
Jan 09, 2021 |
|
S2 E1.2 Successfully Managing Clinical Trials during COVID-19's Second Wave
|
Jan 09, 2021 |
|
S2 E1.1 - How Recent COVID-19 News Affects NAFLD and NASH Patients
|
Jan 09, 2021 |
|
S2 E1 - How Will COVID-19 Affect the Fatty Liver Community in 2021?
|
Jan 07, 2021 |
|
44.4 2020 Year In Review: How Patients and Patient Advocates reacted to a year of lows and high
|
Jan 01, 2021 |
|
44.3 2020 Year In Review: Revisiting the "MAFLD vs. NAFLD" debate
|
Jan 01, 2021 |
|
44.2 2020 Year In Review: Fatty Liver Disease Enters the Public Dialogue in Germany
|
Jan 01, 2021 |
|
44.1 2020 Year in Review: Simplifying NASH Diagnostics Saves Money, improves satisfaction
|
Jan 01, 2021 |
|
2020 Year-End NASH Review 2: Patient Treatment and Perspectives
|
Dec 30, 2020 |
|
43.4 2020 Year in Review: The Law of Unintended Consequences Blesses NASH Drug Development
|
Dec 25, 2020 |
|
43.3 2020 Year in Review: Progress in developing clinical endpoints necessary to support drug approvals
|
Dec 25, 2020 |
|
43.2 2020 Year In Review: Emergence of Non-Invasive Tests and Testing Strategies in fatty Liver Disease
|
Dec 25, 2020 |
|
43.1 2020 Year in Review: Advances in Fatty Liver Disease Drugs and Diagnostics
|
Dec 25, 2020 |
|
2020 Year-End NASH Review 1: Drugs and Diagnostics - Ep 43
|
Dec 24, 2020 |
|
Policy 2: Credibility, Convergence and the 2021 Global Liver Institute Action Plan - Ep 42
|
Dec 17, 2020 |
|
Policy 1: The Liver Policy Agenda Has Experienced Surprising Success in the Last Four Years - Ep 41
|
Dec 10, 2020 |
|
Links between NAFLD and Cardiovascular Disease - Ep 40
|
Dec 03, 2020 |
|
COVID CHAOS: The 2nd Wave - Ep 39
|
Nov 24, 2020 |
|
The Day After TLMdX 2020 Wrapping Up with The View from Across the Atlantic - Ep 38
|
Nov 19, 2020 |
|
Day Four of TLMdX 2020 - Monday at the Digital Liver Meeting -- Getting Better at Diagnostics and Drugs, Not Education - Ep 37
|
Nov 17, 2020 |
|
Day Three of TLMdX 2020 - Sunday at The Digital Liver Meeting -- The Future Looks Bright! - Ep 36
|
Nov 16, 2020 |
|
Day Two of TLMdX 2020 - Lean NASH, exciting Diagnostics and Patient-Reported Outcomes as an Endpoint - Ep 35
|
Nov 15, 2020 |
|
Why NASH Drug Trials Fail: A Thoughtful, Challenging Theory - Ep 34
|
Nov 12, 2020 |
|
Previewing The Digital Liver Meeting (TLMDx from AASLD): Part Two - Ep 33
|
Nov 05, 2020 |
|
Previewing The Digital Liver Meeting (TLMDx from AASLD): Part One - Ep 32
|
Oct 29, 2020 |
|
How Have The Events of 2020 Affected Patient Treatment In The Clinic? Ep 31
|
Oct 22, 2020 |
|
Six Months In: How COVID-19 Has Changed Our World!
|
Oct 15, 2020 |
|
COVID-19 and the Liver, “it's complicated - Ep 29
|
Oct 08, 2020 |
|
Wild Times in NASH-Ville Part 3: Better Days ARE Ahead! Ep 28
|
Oct 01, 2020 |
|
Crystal Ball Tells Us The Most Important Stories Of Autumn - Ep 27
|
Sep 24, 2020 |
|
"Beond the Biopsy" How NASH Therapy Will Improve When Non-Invasive Tests Become The Standard - Ep 26
|
Sep 17, 2020 |
|
What Exactly Are We Trying To Achieve In Early-Stage NASH Therapy? Ep 25
|
Sep 10, 2020 |
|
EASL Digital ILC 2020 Wrap-Up: A Complicated Picture Emerges - Ep 24
|
Sep 02, 2020 |
|
Digital ILC Day Three Highlights: Late breakers, COVID and more - Ep 23
|
Aug 29, 2020 |
|
Digital ILC Day Two Highlights: A Fork in the Road - Ep 22
|
Aug 28, 2020 |
|
Digital ILC Day One Highlights: Much to Think About - Ep 21
|
Aug 28, 2020 |
|
How will Digital ILC be different from past conferences? - Ep 20
|
Aug 27, 2020 |
|
What NASH patients want from outside the healthcare system - Ep 19
|
Aug 20, 2020 |
|
What NASH Patients Want From the Healthcare System - Ep 18
|
Aug 13, 2020 |
|
Previewing EASL: Part 2 - Ep 17
|
Aug 06, 2020 |
|
Nurses Helping NASH Patients - Ep 16
|
Jul 30, 2020 |
|
Previewing EASL: Part 1 - Ep 15
|
Jul 23, 2020 |
|
Respect For The Liver - Ep 14
|
Jul 16, 2020 |
|
Diagnosing Diagnostics III: Better Tools on the Way - Ep 13
|
Jul 09, 2020 |
|
What Does “No” Mean to FDA? - Ep 12
|
Jul 02, 2020 |
|
Crystal Ball Tells Us the Most Important Story of the Summer - Ep 11
|
Jun 27, 2020 |
|
Diagnosing Diagnostics II: Tools vs. Teaching - Ep 10
|
Jun 18, 2020 |
|
International NASH Day is Here! - Ep 9
|
Jun 11, 2020 |
|
Diagnosing Diagnostics – Part I - Ep 8
|
Jun 04, 2020 |
|
NASH-Ville - Part 2: Better Days Ahead? - Ep 7
|
May 28, 2020 |
|
What’s in a Name: NAFLD or MAFLD? - Ep 6
|
May 21, 2020 |
|
Wild Times In NASH-Ville – Part I - Ep 5
|
May 15, 2020 |
|
When You Get To A Fork In The Road - Ep 4
|
May 07, 2020 |
|
C-Suite COVID-19 Challenges - Ep 3
|
Apr 30, 2020 |
|
Five $imple Pieces - Ep 2
|
Apr 23, 2020 |
|
COVID CHAOS - Ep 1
|
Apr 15, 2020 |